AWARD NUMBER: W81XWH-15-2-0006

TITLE: Mechanisms of Resistance to Chemotherapies Targeting BRCA-Mutant Breast Cancer

PRINCIPAL INVESTIGATOR: Dr. Andre Nussenzweig

CONTRACTING ORGANIZATION: The Geneva Foundation
Tacoma, WA 98402

REPORT DATE: December 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. REPORT DATE (DD-MM-YYYY)  December 2016  2. REPORT TYPE  ANNUAL
3. DATES COVERED (From - To)  01 Dec 2015 – 30 Nov 2016

4. TITLE AND SUBTITLE
Mechanisms of Resistance to Chemotherapies Targeting BRCA-Mutant Breast Cancer

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-15-2-0006

5c. PROGRAM ELEMENT NUMBER

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

6. AUTHOR(S)
Andre Nussenzweig, Ph.D.

Email: jmolstre@genevausa.org

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
The Geneva Foundation
917 Pacific Ave, Suite 600
Tacoma, WA 98402

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)
USAMRAA

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
This research proposal for the BRCP Idea Expansion Award involves a detailed study of the underlying mechanisms of drug resistance in BRCA1 and BRCA2 deficient cells through the genetic manipulation of the major players that mediate homologous recombination and non-homologous end joining DNA repair pathways. These studies will serve as a foundational data set in determining the importance of DNA repair pathways in acquiring resistance to breast and ovarian cancer chemotherapies. Because drug resistance is an inescapable feature of all cancer treatments, an understanding of the causal mechanisms of resistance will undoubtedly provide new opportunities and susceptible targets in cancer therapies.

15. SUBJECT TERMS
Nothing listed

16. SECURITY CLASSIFICATION OF:

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

17. LIMITATION OF ABSTRACT
UU

18. NUMBER OF PAGES
52

19a. NAME OF RESPONSIBLE PERSON
USAMRMC

19b. TELEPHONE NUMBER (include area code)

---

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4-12</td>
</tr>
<tr>
<td>4. Impact</td>
<td>12</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>12-13</td>
</tr>
<tr>
<td>6. Products</td>
<td>13-15</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>15-16</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>16</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>16</td>
</tr>
</tbody>
</table>
1. **INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

In ongoing work being performed in support of the BCRP Idea Expansion Award, we have hypothesized that restoration of homologous recombination (HR) is a critical driver of chemo-resistance in BRCA1/2 mutated breast cancers. Earlier work provided evidence for a novel mechanism of HR restoration, through the inactivation of proteins functioning in an alternate DNA repair pathway called non-homologous end joining (NHEJ). Loss of NHEJ proteins, such as 53BP1, restored normal HR activity in BRCA1 deficient cells and rendered these cells resistant to chemotherapeutic agents. Under the aegis of the Idea Expansion Award, we have discovered a novel and unexpected mechanism of drug resistance in BRCA-deficient cancers that involves the loss of the 53BP1-interacting protein PTIP that operates independently of the re-establishment of HR. Overall, the major aim of this research is to understand the manifold routes that lead to acquired resistance in breast cancer treatment and how altering the balance between NHEJ, HR and other pathways can be exploited to overcome the Achilles heel of acquired resistance.

2. **KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

1. 53BP1: p53 Binding Protein 1
2. Brca1 & 2: Breast cancer type 1 & 2 susceptibility protein, tumor suppressor
3. BRCT domain: BRCA1 Carboxy Terminal Domain
4. CD19: Cluster of Differentiation 19
5. CRE: Causes Recombination
6. DSB: Double Strand Breaks
7. H2AX- a variant of Histone 2A, a core chromatin protein
8. HR: Homologous Recombination
9. H2AX: Histone 2A
10. MEFs: Mouse Embryonic Fibroblasts
11. NHEJ: Non-Homologous End Joining
12. PALB2: PArtner and Localizer of BRCA2
13. PARP: Poly ADP-Ribose Polymerase
14. PARPi: Poly ADP-Ribose Polymerase Inhibitor
15. PTIP: Pax Transactivation Domain-Interacting Protein
16. RAP80: Receptor-Associated Protein 80
17. RIF1: RAP1 Interacting Factor 1
18. RNF8: Ring Finger protein 8
19. RNF168: Ring Finger protein 168
20. RPA: Replication Protein A
21. TCGA: The Cancer Genome Atlas

3. **ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the USAMRAA Grants Officer whenever there are significant changes in the project or its direction.

- What were the major goals and objectives of the project?
- What was accomplished under these goals?
- What opportunities for training and professional development did the project provide?
- How were the results disseminated to communities of interest?
- What do you plan to do during the next reporting period to accomplish the goals and objectives?

**What were the major goals of the project?**

In this proposal, we outlined two major Specific Aims and Goals.

In **Specific Aim 1**, we proposed the use of a genetic approach to define interactions between NHEJ and HR effectors that regulate DNA repair pathway selection (24 months). In specific **Sub-Aim 1a**, we intend to test the hypothesis
that elevated levels of chromatin bound 53BP1 converts wild type cells to a ‘BRCA-deficient’ state in the context of drug sensitivity and genome stability. In specific **Sub-Aim 1b**, the importance of PTIP associated proteins (PA1 and MLL4) and the functional domains within PTIP necessary for HR reconstitution are to be evaluated by *in vivo* experimentation.

Overall, in **Specific Aim 2**, we proposed testing the contribution of the 53BP1 associated protein (PTIP) in influencing repair pathway selection and to also computationally interrogate clinical data sets together with data acquired from murine models to understand the mechanisms of chemo-resistance in BRCA1- and BRCA2-mutated cancers (24 months). In specific **Sub-Aim 2a**, we are testing the hypothesis that PTIP can influence repair pathway selection and drug sensitivity. In specific **Sub-Aim 2b**, we plan on using gene expression data and other genome-wide data sets from clinical databases to implicate known (and novel) proteins involved in the regulation of chemoresistance.

**What was accomplished under these goals?**

**A. RNF168 and 53BP1 levels modulate PARP inhibitor-induced genome instability in BRCA1 deficient cells**

In our 2015 Annual Report, we addressed how interactions between NHEJ and HR proteins influenced repair pathway selection (**Specific Aim 1**). Specifically, we asked whether increased expression of RNF168, a RING domain E3-ubiquitin ligase or 53BP1 impacted physiological NHEJ, such as immunoglobulin class switch recombination (CSR), versus mutagenic NHEJ (defined as NHEJ conducted during S phase which typically results in genome instability). We found that the anti-resection activities of 53BP1 are rate-limiting for mutagenic NHEJ but not for physiological CSR. An implication of our results is that deregulation of the RNF168/53BP1 pathway could alter the chemosensitivity of BRCA1 deficient tumors. The work leading to the conclusions detailed above was published in May 2015: ‘**Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining**’. Zong D, Callén E, Pegoraro G, Lukas C, Lukas J, Nussenzweig A. *Nucleic Acids Res.* 2015 May 26;43(10):4950-61.

**A1. Studies being conducted currently** are designed to probe functional interactions between RNF168 and BRCA1/2 in the DNA damage response and tumorigenesis. The repair of DNA double strand breaks (DSBs) by homologous recombination is mediated by a complex containing BRCA2 and PALB2 (Partner and Localizer of BRCA2), which loads the recombinase Rad51 onto resected DNA ends in order to initiate strand invasion into the intact repair template present in the sister chromatid. We are exploring the presence of an alternative pathway for the recruitment of the PALB2/BRCA2 complex that may be dependent on the ubiquitin ligase activity of RNF168. Specifically, we are interested in characterizing the molecular interactions between RNF168 and PALB2/BRCA2 using biochemical assays and aim to identify the domains in RNF168 and PALB2 that are required for this interaction. We also plan to use mass spectrometry to identify any hitherto unknown interaction partners of RNF168 and characterize their importance to genome maintenance.

It is well known that patients with germline BRCA1 mutations are dramatically predisposed to the development of mammary and ovarian tumors. The reason(s) for this remarkable tissue specificity is not known. One possibility that has not been evaluated is whether differences in the expression of certain genes in mammary/ovarian tissues may render them especially vulnerable to the loss of a single BRCA1 allele. We are in the process of investigating whether BRCA1-associated tumors arise from lower expression of RNF168 compared to other cell types. If BRCA1 heterozygous cells deleted for RNF168 are exquisitely sensitive to clinically used chemotherapeutic agents, including PARP inhibitors and cisplatin, this raises the possibility that **BRCA1-mutated tumors** with low expression levels of RNF168 may be uniquely responsive to platinum-based and PARPi treatment. We are in the midst of testing this hypothesis through data mining of TCGA databases and the use of appropriate mouse tumor models that mimic human mammary tumorigenesis (**Specific Aim 2, Sub-Aim 2b**).

**B. Replication fork protection by the prevention of nascent DNA strand degradation is strongly co-related with chemoresistance in BRCA1/2-deficient cells**

Cells deficient in the BRCA1 and BRCA2 genes have a reduced capacity to repair DNA double-strand breaks by homologous recombination and consequently are hypersensitive to DNA-damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors. In work germane to the specific aims of this grant, we showed that
loss of the MLL3/4 complex protein, PTIP, protects BRCA1/2-deficient cells from DNA damage and rescued the lethality of BRCA2-deficient embryonic stem cells. However, PTIP deficiency did not restore homologous recombination activity at double-strand breaks. Instead, its absence inhibited the recruitment of the MRE11 nuclease to stalled replication forks, which in turn protected nascent DNA strands from extensive degradation. More generally, acquisition of PARP inhibitors and cisplatin resistance was associated with replication fork protection in BRCA2-deficient tumour cells that did not develop BRCA2 reversion mutations. Disruption of multiple proteins, including PARP1 and CHD4, led to the same end point of replication fork protection, highlighting the complexities by which tumour cells evade chemotherapeutic interventions and acquire drug resistance.

In a parallel and complementary study, we examined the effect of PARPi (olaparib) on HR-proficient cells. Olaparib pretreatment, PARP1 knockdown or Parp1 heterozygosity of BRCA2cko/ko mouse embryonic stem cells (mESCs), carrying a null (ko) and a conditional (cko) allele of BRCA2, resulted in viable Brca2ko/ko cells. PARP1 deficiency did not restore HR in Brca2ko/ko cells, but instead protected stalled replication forks from MRE11-mediated degradation through its impaired recruitment. The functional consequence of PARP1 heterozygosity on BRCA2 loss is demonstrated by a significant increase in tumorigenesis in BRCA2cko/cko mice. Thus, while olaparib efficiently killed BRCA2-deficient cells, we demonstrated that it can also contribute to synthetic viability if PARP is inhibited before BRCA2 loss.


The **Significant Results and Key Outcomes** summarized below highlight data germane to **Specific Aim 2** outlined in this proposal.

## B1. PTIP loss protects RFs in Brca2-deficient cells

Given that BRCA1 and BRCA2 have been ascribed DSB-independent functions during replication stress and since MRE11 has been implicated in mediating replication fork (RF) protection.

![Figure 1: Loss of Ptip in Brca1/3 deficient B cells protects nascent DNA from degradation without restoring HR.](image)

1. **Top Panel (b)**: Schematic for labelling B cells with CldU and IdU, b-e, Ratio of IdU versus CldU upon HU treatment. Numbers in red indicate the mean ± s.d. (NS, not significant; ***, P ≤ 0.0001; ****, P ≤ 0.00001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed for each genotype.
2. **Bottom Panel (c)**: Genomic instability (top) and viability upon HU treatment (bottom) relative to WT upon 6 h of 10 mM HU treatment. (**, P ≤ 0.001; ***, P ≤ 0.05, unpaired t-test.) Fifty metaphases were analysed. Representative images (top) and quantification (bottom) of irradiation (IR)-induced RAD51 foci. ***, P ≤ 0.05, unpaired t-test (n = 120 cells examined). Experiments were repeated three times.
degradation in cell lines, we tested whether primary cells deficient in BRCA1 or BRCA2 also showed degradation of nascent replication tracts. We therefore conditionally inactivated BRCA1 and BRCA2 in B lymphocytes (Brca1f/fCd19Cre; Brca2f/fCd19Cre). B cells were sequentially labelled with CldU-(red) followed by IdU-(green), after which the active RFs were stalled with hydroxyurea (HU) (Fig. 1a). The relative shortening of the IdU tract after HU treatment serves as a measure of RF degradation (Fig. 1a). Upon HU treatment, wild-type (WT) cells showed a mean IdU/CldU tract ratio close to 1 (Fig. 1b). However, Brca1- and Brca2-deficient B cells exhibited a 30–45% reduction in the IdU tract length (Fig. 1b–e). Brca1/Ptip doubly deficient cells exhibited 2.4-fold fewer chromosomal aberrations and increased viability compared with Brca1−/− (Fig. 1f), suggesting that PTIP has functions at stalled RFs distinct from its DSB-dependent interactions with 53BP1 and RIF1.

B2. PTIP loss rescues lethality of Brca2-null ESCs

Loss of Brca2 in ESCs is incompatible with cell survival. To test whether PTIP deficiency could promote ESC survival, we knocked down PTIP in mouse ESCs, which have one null and one conditional allele of Brca2 (Brca2f/f−, Fig. 2a). After CRE transfection in Brca2f/f− ESCs and selection in HAT medium, very few resistant colonies were obtained and these remained Brca2f/f− rather than Brca2-null, reflecting the essential role of BRCA2 in ESC viability (Fig. 2b). Strikingly, 12.5% and 5% of the HAT-resistant colonies were Brca2-null when targeted by Ptip short hairpin RNAs (shRNAs) 1 and 2 respectively (Fig. 2b). Consistent with our analysis of Brca2−/− Ptip−/− B cells (Fig. 1g), irradiation-induced RAD51 foci formation was defective in Brca2/Ptip-deficient ESCs (Fig. 2c, d). Moreover, while efficient gene targeting to the Pim-1 locus was observed in WT ESCs using a promoterless hygromycin cassette (100% of the hygromycin-resistant WT clones were targeted integrations), we did not observe a single targeted clone in Brca2/Ptip-deficient ESCs (Fig. 2e) indicative of defective HR. Nevertheless, stalled RFs in PTIP-deficient Brca2−/− ESCs displayed RF protection compared with Brca2 hypomorphic mutant ESCs (Y3308X)17 (Fig. 2f). Thus, deficiency in PTIP protects RFs from degradation and rescues the lethality of Brca2 knockout ESCs without restoring DSB-induced HR.

B3. MRE11 association at RFs depends on PTIP-MLL3/4

Although the recruitment of PTIP to DSBs after irradiation is dependent on 53BP1, we hypothesized that PTIP might be recruited to sites of stalled RFs independently of its interactions with 53BP1. Consistently, we observed PTIP accumulation at sites of replication stalling marked by pan-nuclear γ-H2AX staining (Fig. 3a). Among cells exhibiting pan γ-H2AX signal, 71.4% of WT and 78% of 53Bp1−/− mouse embryonic fibroblasts (MEFs) exhibited PTIP foci following HU treatment (Fig. 3a). Even in the absence of HU treatment, PTIP exhibited extensive co-localization with proliferating cell nuclear antigen (PCNA) during late S phase both in WT and in 53BP1-deficient cells (Fig. 3b). Collectively, these data suggest that PTIP might function during normal or perturbed replication in a DSB- and 53BP1-independent manner. Like PTIP, MRE11 also associates with chromatin in a DNA damage-independent but DNA replication-dependent manner (Fig. 3c). Loss of PTIP resulted in a marked decrease of MRE11 association with PCNA foci in unperturbed cycling MEFs (Fig. 3c). Re-introduction of WT full-length
PTIP into Ptip−/− MEFs restored MRE11 co-localization with PCNA in late S phase (Fig. 3d). Thus, in contrast to irradiation-induced MRE11 foci, localization of MRE11 to sites of DNA replication is PTIP-dependent (Fig. 3c–e). To monitor MRE11 and RAD51 association with active and stalled RFs we performed iPOND analysis in WT and Ptip−/− MEFs. WT cells showed an increase in MRE11 and RAD51 association with stalled RFs (Fig. 3f). Ptip-deficient cells also showed an increase in RAD51 association at RFs, but MRE11 association with nascent DNA was reduced upon HU treatment (Fig. 3f), consistent with our immunofluorescence analysis (Fig. 3c). Thus, MRE11 deposition on newly synthesized DNA is dependent on PTIP, which itself is recruited to stalled forks upon replication stress.

B4. RF protection confers chemoresistance

RF protection contributes to genome stability in a manner independent of DSB-induced HR. Rif1-deficient cells, characterized by extensive RF degradation (Fig. 1c) showed increased chromosomal aberrations in response to replication poisons PARPi, HU and cisplatin. We therefore speculated that RF stability mediated by loss of PTIP (Fig. 1d, e) might confer genome stability to Brca-deficient cells exposed to chemotherapeutics that poison DNA replication. Indeed, we found that Ptip deficiency reduced the levels of chromosomal aberrations both in Brca1−/− and in Brca2−/− B cells (Fig. 4a, b). Taken together, these data suggest that PTIP levels could be a biomarker for acquired resistance to platinum-based chemotherapy in Brca1/2-mutated ovarian cancers.

An unbiased shRNA screen recently demonstrated that reduced levels of the nucleosome remodeling factor CHD4 in Brca2 mutant cancers correlated with poor patient response to chemotherapy, and increased tolerance to DNA-damaging agents without restoration of RAD51-dependent HR. To test whether the resistance mechanism in this case occurs through RF protection, we knocked down CHD4 in the Brca2 mutant ovarian cancer cell line PEO1. While CHD4 depletion in Brca2 mutant cells did not restore HR, we observed that it largely conferred protection to nascent replication tracts from degradation upon HU treatment (Fig. 4c). Moreover, depletion of CHD4 resulted in significantly decreased recruitment of MRE11 upon HU treatment in Brca2 mutant cells (data not shown). These results suggest that MRE11-mediated degradation contributes to genome instability upon treatment with replication poisons. To test this idea, we pre-incubated Brca2-deficient B cells with the MRE11 nuclease inhibitor mirin before treating with PARP inhibitor or cis-platin. Mirin treatment did not alter the frequency of replicating cells monitored by EdU incorporation (data not shown). However, incubation with mirin reduced the levels of PARPi-induced chromosomal aberrations approximately twofold. Similarly, Brca2-deficient cells were partly protected from cisplatin-induced DNA damage when MRE11 nuclelease activity was inhibited (data not shown). We concluded that MRE11 nuclease promotes genomic instability in Brca2-deficient cells.

Since PARP1 (ARTD1) is required for MRE11 localization to stalled replication forks and its loss rescues the embryonic lethality in Brca2-null ESCs, we tested the contribution of PARP1 to RF stability and genome integrity by generating Brca1−/−Parp1−/− B cells (Brca1f/f; Parp1−/−; Cd19Cre). Loss of Parp1 protected Brca1-deficient RFs from degradation and resulted in a significant reduction in chromosomal aberrations (Fig. 4d, e). Thus, despite the fact that treatment with PARP inhibitor increases levels of DNA damage in Brca1-deficient cells, loss of Parp1 before Brca1 loss protects against genome instability. To determine whether Brca2-deficient tumour cells acquire chemotherapy resistance via RF protection, we induced PARPi-resistance using the KB2P mouse model for Brca2-deficient breast cancer (Fig. 5a). A mammary tumour from KB2P mice was transplanted into syngeneic FVB mice and, when the tumour reached a size >200 mm3, mice were treated with PARPi (AZD2461) for 28 consecutive
days. The tumour was initially responsive to treatment but eventually grew, upon which treatment was repeated until PARPi resistance was achieved (Fig. 5c). The stability of acquired resistance was confirmed by re-transplanting matched naive and resistant tumours and treating the animals with vehicle or AZD2461 (Fig. 5d). PARPi-resistant tumours also showed cross-resistance to replication poisons topotecan and cisplatin (Fig. 4f, g). Both naive and resistant Brca2-deficient tumours showed impaired irradiation-induced RAD51 foci formation (Fig. 5e, f). We therefore assayed naive and resistant tumours ex vivo for RF stability. The mean length of the CldU and the IdU tracts were similar in all samples that were not treated with HU (Fig. 4h and Fig. 5g). While naive tumour cells showed degradation of nascent tracts upon HU treatment, resistant tumour cells were protected (Fig. 4h). These data suggest that RF protection rather than restoration of HR may be the main mechanism for acquired resistance in this mammary tumour.

Overall Conclusions
Our study and data not shown from ‘Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies’ by Ding X et al., Nat Comm. Aug 2016 provide the first examples of genetic alterations that bypass the essential requirement for DSB-induced HR, evidenced by the finding that reductions in PTIP or PARP1 levels rescues the lethality of Brca2-null ESCs. We speculate that the reason Brca2 nullizygosity is compatible with viability is because RAD51 is able to perform essential HR functions (such as SCE) by loading onto RFs independently of BRCA2, even if RAD51 loading onto processed DSBs is strictly dependent on BRCA2 (Fig. 1g and Fig. 2c, d). We also show that loss of PTIP, PARP1 and CHD4 confers resistance to a variety of DNA-damaging agents in Brca-deficient cells. Resistance to PARPi and cisplatin both in primary and in tumour cells grown in vitro or in vivo correlates with protection from RF degradation. While 53BP1 disruption rescues the viability of Brca1-deficient mice by restoration of HR, cells from these animals show residual levels of chromosomal aberrations. The significant level of RF degradation observed in Brca1−/−53Bp1−/− cells (Fig. 1b) may contribute to this genome instability. Since RF degradation is mediated by MRE11, we propose that persistence of MRE11 at stalled forks is toxic and normally counteracted by BRCA1/2. One possibility is that MRE11 could initially be recruited to stalled forks to mediate RF restart, and that BRCA1/2 is necessary to subsequently disengage MRE11 from already-processed DNA termini. Consistently, we have found a significant increase in chromatin-bound MRE11 in Brca2-deficient cells treated with HU or cisplatin. We therefore propose that deficiencies in PTIP, CHD4 and PARP1 could confer drug resistance in Brca-deficient cells by limiting the access of MRE11 to single-strand DNA at stalled RFs.

In summary, we have shown that protection of nascent DNA from degradation provides a mechanism that can promote synthetic viability and drug resistance in Brca-deficient cells without restoring HR at DSBs.
Summary of Methodologies Employed

Mice, MEFs, and B cell cultures. The 53Bp1−/−, BrcalfΔ11)fΔ11) (NCI mouse repository), Brca2f/f (NCI mouse repository), Rif1f/f, Ptipf/f and Mll4f/f mice have been described. To generate Mll4-SET-flox/flox mice, exons 50–51 of the Mll4/Kmt2d gene were flanked by loxP sites. Cre-mediated deletion of the floxed exons 50–51 causes frame shift and generates a stop codon in exon 52. The resulting protein lacks the carboxy (C)-terminal 276 amino acids including the entire enzymatic SET domain. Resting splenic B cells were isolated from 8- to 12-week-old WT or mutant spleen with anti-CD43 microbeads (anti-Ly48; Miltenyi Biotech) and were cultured with LPS (25 μg/ml; Sigma), IL-4 (5 μg/ml; Sigma) and RP105 (0.5 μg/ml; BD). Stimulated B cells were additionally infected with CRE to ensure a high level of gene deletion in these cells. All mice were randomly distributed in experimental groups after genotyping. WT MEFs were immortalized by SV40 retroviral infection, and SV40 immortalized Ptipf/f and Mll3−/−Mll4f/f MEFs were infected with a CRE retrovirus to delete Ptip and Mll4 respectively. Coding sequences for mouse Ptip–GFP were cloned into the MIGR1 retroviral vector as previously described.

Generation of CHD4-deficient PEO1 lines using RNAi. BRCA2-mutated ovarian cancer cell lines PEO1 were grown in DMEM with 10% FBS and 1% Glutmax. RNAi for CHD4 was performed. ESC lines, shRNA knockdowns and rescue of BRCA2 viability. PL2F2 mouse ESCs were maintained in M15 media (Knockout DMEM with 15% fetal bovine serum, 0.00072% β-mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin and 0.292 mg/ml l-glutamine) at 37 °C, 5% CO2. ESCs were plated on a monolayer of mitotically inactive feeder cells. Two different shRNAs against Ptip mRNA were cloned into pSuperior vector (Oligoengine). shRNA sequences are listed below with the targeted sequences underlined: mPtip shRNA-1 sense, 5′GATCCCC GTGGCGCTCTCCTGCCAGT TTCAAGAGA ACTGGCAGGAGAGCGCCAC TTTTTA 3′; mPtip shRNA-1 antisense, 5′ AGCTTAAAAA GTGGCGCTCTCCTGCCAGT TCTCTTGAA = =

Figure 5: Bru2α-deficient/unmethylated PARPs resistance to restoration of RAD51 foci formation. a. Schematic depicting the conditional 3RCA2 alleles of the KEBP (Cre/Cre;Bru2α:p53F) mouse. Normal Bru2α function is required for resistance to PARPs (black arrow). b. The stability of BRCA2 function in the Bru2α foci for 20 consecutive days was analyzed when the tumor reached 200 mm3 (n = 100). c, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml). d, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml). e, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml). f, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml). g, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml). h, PARP-deficiency of the KEBP tumor (relative tumor volume in 3RCA2 mice). The treatment with 2000 mgMT (100 μg/ml) for 2 days was terminated with irradiation at 2000 mgMT (100 μg/ml).
ACTGGCAGGAGGCACCACGG3'; mPtip shRNA-2 sense, 5’GATCCCC CCGTAGCAACACAGTCTCTTCA
TTCAAGAG GAGCAGTGTGTGTGCTACGG
TTTTTA 3'; mPtip shRNA-2 antisense, 5’ AGCTTAAAAA CCGTAGCAACACAGTCTCT TCTCTTGAA
GAGCAGTGTGTGTGCTACGG GG3’. shRNA vectors were linearized by Scal and electroporated into ESCs
using a Bio-Rad gene pulser. Cells were selected in G418 (0.18 mg/ml) 24 h after electroporation for 5 days.
Individual colonies were picked and PTIP levels were determined by western blotting. The PGK-Cre plasmid
was electroporated into Ptip shRNA knockout cells (20 μg DNA for 1 × 10⁷ cells). Thirty-six hours after
electroporation, HAT (hypoxanthine–aminopterin–thymidine) selection was performed for 5 days, after which cells
were switched to HT (hypoxanthine–thymidine) media for 2 days and then transferred to normal media. Colonies
were picked when visible, genomic DNA was extracted and Southern blotting was performed. For PCR genotyping,
the following primers were used to amplify the Brca2 cko allele and Brca2-KO allele: Brca2-KO forward, 5’
GCCACCTCTGCTGATTCTA; Brca2-KO reverse, 5’ AAAGAACCAGCTGGGCTCGAG; Brca2-flox forward,
5’ TG AAGTGGACCTGTAAACC; Brca2-flox reverse, 5’ AGTTCTCTCCTTTCA GCCTTC.

DNA fibre analysis. Asynchronous B cells, BRCA2-mutated PEO1 cells and Brca2-deficient K2BP tumours were
labelled with 30 μM CldU, washed with PBS and exposed to 250 μM IdU. After exposure to IdU, the cells were
washed again in warm PBS and treated or not with HU before collection. Cells were then lysed and DNA fibres
stretched onto glass slides, as described42. The fibres were denatured with 2.5 M HCl for 1 h, washed with PBS and
blocked with 2% BSA in phosphate buffered saline Tween-20 for 30 min. The newly replicated CldU and IdU tracts
were revealed with anti-BrdU antibodies recognizing CldU and IdU respectively. Images were taken at 60 ×
magnification (Zeiss Axio Observer.Z1), and statistical analysis was performed using GraphPad Prism.
DSB detection by PFGE. DSB detection by PFGE was done. Ethidium-bromide-stained gels were analysed using an
UVP EC3 imaging system. Quantification was performed using ImageJ normalizing DSB signals to unsaturated
DNA signals in the well. Relative DSB levels were obtained by comparing treatment results to the background DSB
signals observed for untreated conditions.

Western blotting and immunofluorescence. Primary antibodies were used at the following dilutions: anti-tubulin
(1:15,000, Sigma), anti-H3K4me3 (1:5,000, Millipore), anti-H3K4me1 (1:5,000, Millipore), anti-RAD51 (1:50,
Santa Cruz), anti-PCNA (1:2,000, Santa Cruz), anti-total H3 (1:1,000 Millipore) and anti-Mre11 (1:10,000, gift from
J. Petrini, MSKCC). MEFs were prepared for immunofluorescence by growth on 18 mm × 18 mm glass cover slips.
Lymphocytes were dropped onto slides coated with CellTak (BD Biosciences). Cells were fixed with methanol and
incubated with primary antibody.

iPOND and flow cytometry. iPOND was performed as follows: one hundred and fifty million WT, Pti−/− and
Mll3−/−Mll4−/− MEFs were labelled with 10 μM EdU (Life Technologies) and treated with HU as indicated. Two
hundred million cells were used for iPOND experiments with ESCs. Cells were cross-linked with 1% formaldehyde
for 10 min at room temperature, quenched with 0.125 M glycine and washed with PBS. For the conjugation of EdU
with biotin azide, cells were permeabilized with 0.25% Triton X-100/ PBS, and incubated in click reaction buffer
(10 mM sodium l-ascorbate, 20 μM biotin azide (Life Technologies), and 2 mM CuSO4) for 2 h at room
temperature. Cells were resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, and 1% SDS) supplemented with
protease inhibitors (Roche), and chromatin was solubilized by sonication in a Bioruptor (Diagenode-Pico) at 4 °C
for 24 min. After centrifugation, clarified supernatants were incubated for 1 h with streptavidin-MyOne C1 beads
(Life Technologies). Beads were washed and captured proteins were eluted by boiling beads in 2 × NuPAGE LDS
Sample Buffer (Life Technologies) containing 200 mM DTT for 40 min at 95 °C. Proteins were resolved by
electrophoresis using NuPAGE Novex 4–12% Bis-Tris gels and detected by western blotting with the indicated
antibodies. For flow cytometric analysis, asynchronous B cells were pulsed with 10 mM EdU for 20 min at 37 °C
and stained using the Click-IT EdU Alexa Fluor 488 Flow Cytometry Assay Kit.

What opportunities for training and professional development has the project provided?

The project has presented numerous opportunities for the Principal Investigator (Dr. Andre Nussenzweig) and two
post-doctoral fellows (Drs. Arnab Ray Chaudhuri and Dali Zong) to present their work in symposia at the NIH
and at national and international conferences (see details in Section 6 below).
How were the results disseminated to communities of interest?

Results were shared with the scientific community via informal discussions, posters and presentations at scientific meetings and through publications in peer-reviewed journals.

What do you plan to do during the next reporting period to accomplish the goals?

We will continue to pursue the goals outlined in Specific Aims 1 and 2, specifically focusing on dissecting the mechanisms underlying replication fork degradation/protection in BRCA1/2-deficient cells.

4. IMPACT: This component is used to describe ways in which the work, findings, and specific products of the project have had an impact during this reporting period. Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

- the development of the principal discipline(s) of the project;
- other disciplines;
- technology transfer; or
- society beyond science and technology.

What was the impact on the development of the principal discipline(s) of the project?

Work in support of both Specific Aims of this proposal highlight mechanisms that can alter drug sensitivity or resistance in BRCA-deficient tumors. We have also observed that deregulation of the RNF168/53BP1 pathway can alter the chemosensitivity of BRCA1 deficient tumors (Specific Aim 1). We have also observed that PTIP or PARP1 deficiencies promote synthetic viability and drug resistance in BRCA-deficient cells without restoring HR (Specific Aim 2).

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS: The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

- Changes in approach and reasons for change.
- Actual or anticipated problems or delays and actions or plans to resolve them.
- Changes that have a significant impact on expenditures.
- Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents.

Changes in approach and reasons for change

Nothing to Report
Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to Report

Changes that had a significant impact on expenditures

Nothing to Report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to Report

6. PRODUCTS: List any products resulting from the project during the reporting period. Examples of products include:

- publications, conference papers, and presentations;
- website(s) or other internet site(s);
- technologies or techniques;
- inventions, patent applications, and/or licenses; and
- other products.

- Publications, conference papers, and presentations

Journal publications.


Books or other non-periodical, one-time publications.

Nothing to Report

Other publications, conference papers, and presentations.

The project has presented numerous opportunities for the Principal Investigator (Dr. Andre Nussenzweig) and two post-doctoral fellows (Drs. Arnab Ray Chaudhuri and Dali Zong) and staff scientist (Dr. Elsa Callen) to present their work in symposia at the NIH and at national and international conferences.

Arnab Ray Chaudhuri: Visiting post-doctoral fellow

Invited Talks:

Sept 2016 Invited talk at the Developmental Therapeutics Branch, NCI, NIH, Bethesda, USA
July 2016 Invited talk at the Netherlands Cancer Institute, Amsterdam, Netherlands.
July 2016  Invited talk at the Department of Molecular Genetics, Erasmus Medical Centre, Rotterdam, Netherlands.

July 2016  Invited talk at the Centre for Chromosome Biology, National University of Ireland, Galway, Ireland

May 2016  Invited talk at Institute of Molecular Cancer Research, University of Zurich, Switzerland.

**Poster Presentations at Meetings:**

May 2016  Abcam Conference on Mechanisms of Recombination, Alicante, Spain

**Dali Zong: Visiting post-doctoral fellow**

No meetings attended in 2016

**Elsa Callen: Staff Scientist**

**Invited Talks:**

Dec 2016  Mount Sinai, New York City, NY, USA

**Andre Nussenzweig: Principal Investigator**

**Invited Talks:**

1. Invited Speaker, Abcam Maintenance of Genome Stability 2016, Panama City, Panama, 2016
2. Invited Speaker, Dana-Farber Cancer Institute/Harvard Cancer Center Seminars in Oncology Lecture Series, Boston, MA, 2016
3. Invited Speaker, 5th Yearly Meeting on DNA Repair, Egmond aan Zee, Netherlands, 2016
7. Invited Speaker, Gordon Research Conference- 2016 Mutagenesis and Genome Alterations, Girona, Spain, 2016
8. Invited Speaker, ICGEB DNA Replication Conference- “At the intersection of DNA replication and genome maintenance: From basic mechanisms to therapeutic opportunities” Trieste, Italy, 2016
10. Invited Speaker, icBEST 2016 DNA Repair Meeting, Chengdu, China, 2016
12. Invited Speaker, Jacques Monod Conference on Transcription-Replication Crosstalk and Genome Instability, Roscoff, France, 2016
13. Invited Speaker, Royal Tropical Institute Annual Meeting on Cancer Genomics, Amsterdam, Netherlands, 2016

- **Website(s) or other Internet site(s)**
  Nothing to Report

- **Technologies or techniques**
  Nothing to Report
• **Inventions, patent applications, and/or licenses**
  
  Nothing to Report

• **Other Products**
  
  Nothing to Report

### 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

Provide the following information on participants:

• what individuals have worked on the project?
• has there been a change in the other active support of the PD/PI(s) or senior/key personnel since the last reporting period? what other organizations have been involved as partners?

**What individuals have worked on the project?**

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort).

**Name:** Dr. Andre Nussenzweig  
**Project Role:** Principal Investigator  
**Researcher Identifier (e.g. ORCID ID):** NA  
**Nearest person month worked:** 3  
**Contribution to Project:** Responsible for the overall direction of the proposed research as well as daily supervision of laboratory activities, personnel, design and interpretation of experiments, preparation of manuscripts and presentations  
**Funding Support:** Salary supported by the Intramural Research Program (IRP)

**Name:** Dr. Arnab Ray Chaudhuri  
**Project Role:** Visiting Fellow  
**Researcher Identifier (e.g. ORCID ID):** NA  
**Nearest person month worked:** 12  
**Contribution to Project:** Developed the replication fiber assay that measures the rates of fork progression and the extent of fork protection/degradation. He has also helped with the design and execution of primary experiments and contributed to the writing of 2 manuscripts (Nature, 2016 and Nature Communications, 2016) related to Specific Aim 2 in this proposal  
**Funding Support:** Salary renumeration from a fellowship with the Human Frontier Science Program

**Name:** Dr. Elsa Callen  
**Project Role:** Visiting Fellow  
**Researcher Identifier (e.g. ORCID ID):** NA  
**Nearest person month worked:** 4  
**Contribution to Project:** Responsible for genetic and biochemical assays designed to understand the contributing genetic factors in DNA repair pathway selection. Dr. Callen also helped with the design and execution of primary experiments related to replication fork protection. She also contributed to the writing of 2
Manuscripts (Nature, 2016 and Nature Communications, 2016) related to Specific Aim 2 in this proposal

Salary supported by the Intramural Research Program (IRP)

**Name:** Dr. Dali Zong

**Project Role:** Visiting Fellow

**Researcher Identifier (e.g. ORCID ID):** NA

**Nearest person month worked:** 12

**Contribution to Project:**

Responsible for genetic and biochemical assays designed to understand the contributing genetic factors in DNA repair pathway selection. He made extensive contributions to the published manuscript (in Nucleic Acids Research, 2015) related to Specific Aim 1 in this proposal

Supported by the Intramural Research Program (IRP)

**Funding Support:**

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to Report

What other organizations were involved as partners?

Nothing to Report

8. **SPECIAL REPORTING REQUIREMENTS:**

Nothing to Report

9. **APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

See Pdfs of published Nature and Nature Communications Pdf
Replication fork stability confers chemoresistance in BRCA-deficient cells

Arnab Ray Chaudhuri1*, Elsa Callen1*, Xia Ding2, Ewa Gogola3, Alexandra A. Duarte3, Ji-Eun Lee4, Nancy Wong5, Vanessa Lafarga6, Jennifer A. Calvo6, Nicholas J. Panzarino6, Sam John1, Amanda Day1, Anna Vidal Crespo1, Binghui Shen1, Linda M. Starneres2, Julian R. de Ruiter1, Jeremy A. Daniel8, Panagiotis A. Konstantinopoulos5, David Cortez10, Sharon B. Cantor6, Oscar Fernandez-Capetillo1, Kai Ge3, Jos Jonkers3, Sven Rottenberg11, Shyam K. Sharan6 & André Nussenzweig1

Cells deficient in the Brca1 and Brca2 genes have reduced capacity to repair DNA double-strand breaks by homologous recombination and consequently are hypersensitive to DNA-damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors. Here we show that loss of the ML3/4 complex protein, PTP, protects Brca1/2−deficient cells from DNA damage and rescues the lethality of Brca2−deficient embryonic stem cells. However, PTP deficiency does not restore homologous recombination activity at double-strand breaks. Instead, its absence inhibits the recruitment of the MRE11 nucleosome to stalled replication forks, which in turn protects nascent DNA strands from extensive degradation. More generally, acquisition of PARP inhibitors and cisplatin resistance is associated with replication fork protection in Brca2−deficient tumour cells that do not develop Brca2 reversal mutations. Disruption of multiple proteins, including PARP1 and CHD4, leads to the same end point of replication fork protection, highlighting the complexities by which tumour cells evade chemotherapeutic interventions and acquire drug resistance.

The role of BRCA1 and BRCA2 in the repair of double-strand breaks (DSBs) is thought to be central to their tumour-suppressor activities, and underlies the hypersensitivity of Brca1-deficient cells to DNA-damaging agents. While cisplatin and PARP inhibitors (PARPi) have been shown to be effective chemotherapeutic agents, most Brca-mutant carcinomas acquire resistance1. Besides reduced uptake and increased efflux of drugs, the most well-described mechanism that drives chemotherapeutic resistance in Brca1/2−deficient tumours is through the restoration of homologous recombination (HR). Identification of additional mechanisms underlying resistance to DNA damage is crucial for improving therapies and predicting tumour responses in Brca-deficient cancers.

PTIP loss protects RFs in Brca−deficient cells

In addition to their roles in HR, recent studies have uncovered DSB-independent functions for BRCA1 and BRCA2 during replication stress2–4. Since MRE11 has been implicated in mediating replication fork (RF) degradation in cell lines2–4, we tested whether primary cells deficient in BRCA1 or BRCA2 also showed degradation of nascent replication tracts. We therefore conditionally inactivated BRCA1 and BRCA2 in B lymphocytes (Brca1−/CD19Cre; Brca2−/CD19Cre). B cells were sequentially labelled with CldU-(red) followed by IdU-(green), after which the active RFs were stalled with hydroxyurea (HU) (Fig. 1a). The relative shortening of the IdU tract after HU treatment serves as a measure of RF degradation (Fig. 1a). Upon HU treatment, wild-type (WT) cells showed a mean IdU/CldU tract ratio close to 1 (Fig. 1b). However, Brca1− and Brca2-deficient B cells exhibited a 30–45% reduction in the IdU tract length (Fig. 1b–e and Extended Data Fig. 1a–c).

Consistent with previous data2–3, RF degradation in B lymphocytes was dependent on MRE11 exonuclease activity (Extended Data Fig. 1a–c). We also tested the role of DNA2 and the Werner syndrome helicase/nuclease (WRN) in degradation of forks in Brca2−deficient B cells. Treatment of Brca2−deficient cells with WRN inhibitor did not result in fork protection, whereas MRE11 and DNA2 were epistatic (Extended Data Fig. 1c).

Since 53BP1, RIF1, and PTP counteract BRCA1-dependent HR by inhibiting MRE11-dependent DSB resection7–11, we examined whether these factors might also function in RF stability. We thus inactivated BRCA1, BRCA2, RIF1, PTP, and 53BP1 in B lymphocytes (Extended Data Fig. 2a). Short exposure to HU did not promote significant DSB formation (Extended Data Fig. 2b), and fork progression rates were comparable across all genotypes (Extended Data Fig. 2c–f).

Absence of 53BP1 did not protect Brca1−deficient B cells from degradation of RFs (Fig. 1b), consistent with the finding that BRCA1 acts in RF stabilization in a manner independent of DSB repair2,3. Nascent strands also shortened considerably in the absence of the 53BP1 effector Rif1 and in Brca1/Rif1 doubly deficient cells (Fig. 1c). In striking contrast, loss of PTP protected RFs from HU-induced degradation in both Brca1− and Brca2−deficient cells (Fig. 1d, e). Moreover, while Brca1−/−, Rif1−/−, and Brca1−/−/Rif1−/− B cells displayed increased genomic instability when treated with HU (Extended Data Fig. 3a), Brca1/Ptp−/− doubly deficient cells exhibited 2.4-fold fewer chromosomal aberrations and increased viability compared with Brca1−/− (Fig. 1f). Similarly, loss of PTP decreased the number of chromosomal aberrations in Brca2−/− cells challenged with HU (Extended Data Fig. 3b), suggesting that PTP has functions at...
high concentrations of HU. We found that although the percentage of nascent chromatin (see Fig. 3f). Ptip did not enhance the loading of RAD51 on Brca2/Ptip-deficient B cells (Fig. 1g and Data Fig. 3f), but the ability of RAD51 to relocalize to sites of DNA expression of RAD51 or enhanced RAD51 activity. RAD51 levels were from degradation, we asked whether PTIP deficiency leads to over-

Since elevated levels or stabilized RAD51 filaments could protect RFs from degradation without restoring HR. a, Genomic instability of PTIP promotes RF progression and timely restart in Brca2-deficient ESCs (Fig. 2f). Thus, deficiency in PTIP protects RFs from HR at DSBs as measured by isolation of proteins on native DNA (iPOND) analysis (Extended Data Fig. 4e). We also observed similar numbers of spontaneously generated and DNA damage-induced SCEs in WT and Y3308X ESCs. Although Y3308X cells show undetectable levels of irradiation-induced RAD51 formation and loss of targeted integration, indicative of a defect in DSB-induced HR, the basal frequency of SCE was normal in Y3308X cells (Extended Data Fig. 4d). Moreover, RAD51 was enriched on nascent DNA in Y3308X during normal replication and in presence of HU as measured by isolation of proteins on native DNA (iPOND) analysis (Extended Data Fig. 4e). Hence, the synthesis of spontaneously generated and DNA damage-induced SCEs in WT, Brca2-null and Brca2/Ptip-deficient B cells (Extended Data Fig. 4f). Thus, in contrast to RAD51 which is required for DSB- and replication-associated HR, BRCA2 appears to be dispensable for HR.

PTIP loss rescues lethality of Brca2-null ESCs

Since elevated levels or stabilized RAD51 filaments could protect RFs from degradation, we asked whether PTIP deficiency leads to over-expression of RAD51 or enhanced RAD51 activity. RAD51 levels were similar in WT, Ptip−/−, Brca2−/−, and Brca2−/−Ptip−/− cells (Extended Data Fig. 3f), but the ability of RAD51 to relocalize to sites of DNA DSBs was severely impaired in Brca2/Ptip-deficient B cells (Fig. 1g and Extended Data Fig. 3g) and embryonic stem cells (ESCs) (see Fig. 2c, d). Moreover, loss of Ptip did not enhance the loading of RAD51 on nascent chromatin (see Fig. 3f).

Loss of Brca2 in ESCs is incompatible with cell survival. To test whether PTIP deficiency could promote ESC survival we knocked down PTIP in P12F7 mouse ESCs, which have one null and one conditional allele of Brca2 (Brca20/−, Fig. 2a and Extended Data Fig. 4a). After CRE transfection in Brca20/− ESCs and selection in HAT medium, very few resistant colonies were obtained and these remained Brca20− rather than Brca2-null, reflecting the essential role of BRCA2 in ESC viability (Fig. 2b). Strikingly, 12.5% and 5% of the HAT-resistant colonies were Brca2-null when targeted by Ptip short hairpin RNAs (shRNAs) 1 and 2 respectively (Fig. 2b and Extended Data Fig. 4b). Consistent with our analysis of Brca2−/−Ptip−/− B cells (Fig. 1g), irradiation-induced RAD51 foci formation was defective in Brca2/Ptip-deficient ESCs (Fig. 2c, d). Moreover, while efficient gene targeting to the Pim-1 locus was observed in WT ESCs using a promoterless hygromycin cassette (100% of the hygromycin-resistant WT clones were targeted integrations), we did not observe a single targeted clone in Brca2/Ptip-deficient ESCs (Fig. 2e) indicative of defective HR. Similarly, the synthetic HR reporter substrate DR–GFP revealed impaired HR in Brca2/Ptip-deficient ESCs (Extended Data Fig. 4c). Nevertheless, stalled RFs in PTIP-deficient Brca2−/− ESCs displayed RF protection compared with Brca2 hypomorphic mutant ESCs (Y3308X) (Fig. 2f). Thus, deficiency in PTIP protects RFs from degradation and rescues the lethality of Brca2 knockout ESCs without restoring DSB-induced HR.

BRCA2 is dispensable for HR at RFs

It has been suggested that HR at stalled forks is regulated differently from HR at DSBs. As a readout for HR at RFs, we assayed for sister chromatid exchanges (SCEs) in WT and Y3308X ESCs. Although Y3308X cells show undetectable levels of irradiation-induced RAD51 formation and loss of targeted integration, indicative of a defect in DSB-induced HR, the basal frequency of SCE was normal in Y3308X cells (Extended Data Fig. 4d). Moreover, RAD51 was enriched on nascent DNA in Y3308X during normal replication and in presence of HU as measured by isolation of proteins on native DNA (iPOND) analysis (Extended Data Fig. 4e). We also observed similar frequencies of spontaneously generated and DNA damage-induced SCEs in WT, Brca2-null and Brca2/Ptip-deficient B cells (Extended Data Fig. 4f). Thus, in contrast to RAD51 which is required for DSB- and replication-associated HR, BRCA2 appears to be dispensable for HR.
that uses the nascent sister chromatid to repair DNA lesions during replication.

**MRE11 association at RFs depends on PTIP–MLL3/4**

Although the recruitment of PTIP to DSBs after irradiation is dependent on 53BP1 (Extended Data Fig. 5a, b)10, we hypothesized that PTIP might be recruited to sites of stalled RFs independently of its interactions with 53BP1. Consistently, we observed PTIP accumulation at sites of replication stall marking by pan-nuclear γ-H2AX staining30. Among cells exhibiting pan-γ-H2AX signal, 71.4% of WT and 78.6% of 53Bp1−/− mouse embryonic fibroblasts (MEFs) exhibited PTIP foci following HU treatment (Fig. 3a and Extended Data Fig. 5c). Even in the absence of HU treatment, PTIP exhibited extensive co-localization with proliferating cell nuclear antigen (PCNA) during late S phase both in WT and in 53Bp1-deficient cells (Fig. 3b and Extended Data Fig. 5d, e). Collectively, these data suggest that PTIP might function during normal or perturbed replication in a DSB- and 53BP1-independent manner. Like PTIP, MRE11 also associates with chromatin in a DNA damage-independent but DNA replication-dependent manner31 (Fig. 3c). Loss of PTIP resulted in a marked decrease of MRE11 association with PCNA foci in unperturbed cycling MEFs (Fig. 3c) and defective MRE11 recruitment to ssDNA regions upon HU treatment (Extended Data Fig. 5f). Re-introduction of WT full-length PTIP into Pip−/− MEFs restored MRE11 co-localization with PCNA in late S phase (Fig. 3d).

In contrast to irradiation-induced MRE11 foci, localization of MRE11 at RFs we performed iPOND analysis in WT and Pip−/− MEFs expressing GFP-tagged PTIP were either treated or not (NT) with 4 mM HU and assessed for γ-H2AX (red) and PTIP (green). DAPI (4′,6-diamidino-2-phenylindole) indicated in blue. Quantification in Extended Data Fig. 5c. b, Co-localization of PCNA (magenta) and PTIP (green). Quantification in Extended Data Fig. 5d. c, Co-localization of PCNA (green) and MRE11 (red). Quantification in lower panel (n = 150 cells examined). d, Pip−/− MEFs infected with either empty vector (EV) containing IRES–GFP) or full-length PTIP (GFP–PTIP) and probed for GFP (green), MRE11 (red) and PCNA (magenta). Quantification in lower panel (n = 150 cells examined). e, MRE11 (red) and γ-H2AX (green) irradiation-induced foci. Quantification in Extended Data Fig. 5g. f, iPOND analyses of proteins at replication forks (capture). Input represents 0.25% of the total cellular protein content. RAD51 and MRE11 restoration in perfectly synapsed DNA is dependent on HU treatment (Extended Data Fig. 5i)32.
PTIP is also known to constitutively associate with PARP and with ML3/MLL4 histone methyltransferases which catalyse methylation of histone H3 at lysine 4 (refs 23, 24). To identify the region of PTIP that promotes RF degradation in Brca2-deficient cells, we expressed EV (empty vector), FL (full-length PTIP), W165R (disrupting interactions with PARP)25,26, W663R (disrupting interactions with 53BP1 at DSBs)25 or Del-BRCT5-6 (disrupting interaction with ML3/4 independently of DSBs)23,24,26 in Brca2/PTIP doubly deficient cells. We observed that only reconstitution of Brca2/PTIP-deficient cells with PTIP-Del-BRCT5-6 maintained fork protection (Extended Data Fig. 6a).

We therefore tested whether the recruitment of MRE11 at stalled forks was dependent on ML3/4. We observed that MRE11 association at RFs was dependent on ML3/4 as monitored by iPOND and immunofluorescence analysis (Extended Data Fig. 6b, c). We also observed an enrichment of H3K4me1 and H3K4me3 at nascent forks upon HU treatment that was PTIP- and ML3/4-dependent (Fig. 3f and Extended Data Fig. 6b). Thus, deposition of PTIP on nascent forks correlates with the establishment of H3K4me1 and H3K4me3 at RFs.

To determine whether ML4 contributes to degradation of stalled forks in Brca2-deficient cells, we examined RF degradation in Brca1−/−, Brca2−/−, and Brca2−/−/ML4−/− B cells. Brca1−/−ML4−/− and Brca2−/−/ML4−/− cells displayed a partial rescue of fork degradation (Extended Data Fig. 6d, e). To test whether ML4 methylesterase activity is critical, we targeted the catalytic SET domain of MLL4 in Brca2−/− cells. We observed a significant rescue of fork degradation in Brca1−/−/ML4−SET−/−/cells, suggesting that the methylesterase activity is important for promoting fork degradation (Extended Data Fig. 6f).

**RF protection confers chemoresistance**

RF protection contributes to genome stability in a manner independent of DSB-induced HR,3,5. Consistently, we observed that Brca2−/−/ML4−/− B cells showed a partial rescue of chromosomal aberrations upon PARPi and cisplatin treatment compared with Brca2−/− cells alone (Extended Data Fig. 6g). However, Rif1-deficient cells, characterized by extensive RF degradation (Fig. 1c) but normal irradiation-induced RAD51 foci formation (Extended Data Fig. 7a), showed increased chromosomal aberrations in response to replication poisons PARPi, HU and cisplatin (Extended Data Figs 3a and 7b, c)27. We therefore speculated that RF stability mediated by loss of PTIP might confer genome stability to Brca1-deficient cells exposed to chemotherapeutics that poison DNA replication. Indeed, we found that Ptp deficiency reduced the levels of chromosomal aberrations both in Brca1−/− and in Brca2−/− B cells (Fig. 4a, b).

To test whether differential levels of PTIP expression could be an indicator of patient responses to platinum chemotherapy, we queried clinical information from The Cancer Genome Atlas (TCGA) of patients with BRCA1/BRCA2-mutated ovarian serous adenocarcinoma treated with platinum chemotherapy (Extended Data Fig. 8a, b). Survival analysis demonstrated that platinum-treated Brca2 mutants with high PTIP expression were correlated with a longer progression-free survival (PFS) (Extended Data Fig. 8a). Lower expression of PTIP also predicted a shorter PFS in Brca2-associated ovarian cancers (Extended Data Fig. 8b). Taken together, these data suggest that PTIP levels could be a biomarker for acquired resistance to platinum-based chemotherapy in Brca1/2-mutated ovarian cancers.

An unbiased shRNA screen recently demonstrated that reduced levels of the nucleosome remodelling factor CHD4 in Brca2 mutant cancers correlated with poor patient response to chemotherapy, and increased tolerance to DNA-damaging agents without restoration of RAD51-dependent HR28. To test whether the resistance mechanism in this case occurs through RF protection, we knocked down CHD4 in the Brca2 mutant ovarian cancer cell line PEO1 (Extended Data Fig. 8c, d). While CHD4 depletion in Brca2 mutant cells did not restore HR28, we observed that it largely conferred protection to nascent replication tracts from degradation upon HU treatment (Fig. 4c).

Moreover, depletion of CHD4 resulted in significantly decreased recruitment of MRE11 upon HU treatment in Brca2 mutant cells (Extended Data Fig. 8e, f).

These results suggest that MRE11-mediated degradation contributes to genome instability upon treatment with replication poisons. To test this idea, we pre-incubated Brca2-deficient B cells with the MRE11 nuclease inhibitor mirin before treating with PARPi or cisplatin. Mirin treatment did not alter the frequency of replicating cells monitored by EdU incorporation (Extended Data Fig. 8g). However, incubation with mirin reduced the levels of PARPi-induced chromosomal aberrations approximately twofold. Similarly, Brca2-deficient cells were partly protected from cisplatin-induced DNA damage when MRE11 nuclease activity was inhibited (Extended Data Fig. 8h).
We conclude that MRE11 nuclease promotes genomic instability in Brca2-deficient cells.

Since PARP1 (ARTD1) is required for MRE11 localization to stalled replication forks\(^ {29}\) and its loss rescues the embryonic lethality in Brca2-null ESCs\(^ {30} \), we tested the contribution of PARP1 to RF stability and genome integrity by generating Brca1\(^ {−/−}\)Parp1\(^ {−/−}\) B cells (Brca1/Parp1/CD19Cre). Interestingly, loss of Parp1 protected Brca1-deficient RFs from degradation and resulted in a significant reduction in chromosomal aberrations (Fig. 4d, e). Nevertheless, Parp1 deficiency failed to rescue irradiation-induced RAD51 foci formation in Brca1-deficient cells (Extended Data Fig. 8i). Thus, despite the fact that treatment with PARP inhibitor increases levels of DNA damage in Brca1-deficient cells\(^ {31,32} \), loss of Parp1 before Brca1 loss protects against genome instability.

To determine whether Brca2-deficient tumour cells acquire chemotherapy resistance via RF protection, we induced PARP1-resistance using the KB2P mouse model for Brca2-deficient breast cancer (Extended Data Fig. 9a)\(^ {33} \). A mammary tumour from KB2P mice was transplanted into syngeneic FVB mice and, when the tumour reached a size >200 mm\(^ 3 \), mice were treated with PARP1 (AZD2461) for 28 consecutive days (Extended Data Fig. 9b, c). The tumour was initially responsive to treatment but eventually grew, upon which treatment was repeated until PARP1 resistance was achieved (Extended Data Fig. 9c). The stability of acquired resistance was confirmed by re-transplanting matched naive and resistant tumours and treating the animals with vehicle or AZD2461 (Extended Data Fig. 9d). PARP1-resistant tumours also showed cross-resistance to replication poisons topotecan and cisplatin (Fig. 4f, g).

Both naive and resistant Brca2-deficient tumours showed impaired irradiation-induced RAD51 foci formation (Extended Data Fig. 9e, f). We therefore assayed naive and resistant tumours \textit{ex vivo} for RF stability. The mean length of the CldU and the IdU tracts were similar in all samples that were not treated with HU (Fig. 4h and Extended Data Fig. 9g). While naive tumour cells showed degradation of nascent tracts upon HU treatment, resistant tumour cells were protected (Fig. 4h). These data suggest that RF protection rather than restoration of HR may be the main mechanism for acquired resistance in this mammary tumour. However, in this case, acquired resistance was not simply due to loss of PTIP or MRE11 proteins (Extended Data Fig. 9h).

**Discussion**

Our study and the accompanying paper\(^ {30} \) provide the first examples of genetic alterations that bypass the essential requirement for DSB-induced HR, evidenced by the finding that reduction in PTIP or PARP1 (ARTD1) levels rescues the lethality of Brca2-null ESCs. We speculate that the reason Brca2 nullizygosity is compatible with viability is because RAD51 is able to perform essential HR functions (such as SCE) by loading onto RFs independently of BRCA2 (Extended Data Fig. 4e), even if RAD51 loading onto processed DSBs is strictly dependent on BRCA2 (Fig. 1g and Fig. 2c, d). We also show that loss of PTIP, PARP1 and CHD4 confers resistance to a variety of DNA-damaging agents in Brca2-deficient cells. Resistance to PARP1 and cisplatin both in primary and in tumour cells grown \textit{in vitro} or \textit{in vivo} correlates with protection from RF degradation. While 53BP1 disruption rescues the viability of Brca1-deficient mice by restoration of HR\(^ {39,40} \), cells from these animals show residual levels of chromosomal aberration. The significant level of RF degradation observed in Brca1\(^ {−/−}\)53Pbp1\(^ {−/−}\) cells (Fig. 1b) may contribute to this genome instability.

Since RF degradation is mediated by MRE11, we propose that persistence of MRE11 at stalled forks is toxic and normally counteracted by BRCA1/2. One possibility is that MRE11 could initially be recruited to stalled forks to mediate RF restart\(^ {4} \), and that BRCA1/2 is necessary to subsequently disengage MRE11 from already-processed DNA termini. Consistently, we have found a significant increase in chromatin-bound MRE11 in Brca2-deficient cells treated with HU or cisplatin (Extended Data Fig. 10 a, b)\(^ 4 \). In \textit{Saccharomyces cerevisiae}, failure to remove MRE11 from single-stranded DNA can lead to hypersensitivity to a variety of clastogens\(^ {34,35} \). We therefore propose that deficiencies in PTIP, CHD4 and PARP1 could confer drug resistance in Brca2-deficient cells by limiting the access of MRE11 to single-strand DNA at stalled RFs.

In summary, we have shown that protection of nascent DNA from degradation provides a mechanism that can promote synthetic viability and drug resistance in Brca2-deficient cells without restoring HR at DSBs.

**Online Content** Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 30 July 2015; accepted 15 April 2016.


Supplementary Information is available in the online version of the paper.

Acknowledgements We thank A. Bhandoola for discussions; K. Wolcott for flow cytometry; K. Faryabi for help with statistical analysis; T. de Lange for Rif1f/f mice, J. Tainer for PFM39, R. Brosh for WRNi and J. Petrini for Mre11 antibodies. This work was supported by the Intramural Research Program of the National Institutes of Health (NIH), the National Cancer Institute and the Center for Cancer Research, and by a Department of Defense grant to A.N. (BCRP DOD Idea Expansion Award, grant 11557134), and the Netherlands Organization for Scientific Research, the Dutch Cancer Society and the Swiss National Science Foundation to S.V. A.R.C. was supported by a Prospective Researcher Award from Swiss National Science Foundation (PBZHP3_147302) and Human Frontier Science Program Long-Term Fellowship (LT000393/2013). S.C. was supported by NIH grant R01 CA176166-01A1; B.S. was supported by NIH grant R01CA085344; and J.A.D. was supported by a grant to the Center for Protein Research from the Novo Nordisk Foundation (NFP14CC0001).

Author Contributions A.R.C., E.C., S.S. and A.N. conceived and planned the study, A.R.C., E.C. and X.D. designed, performed experiments and analysed data on B cells, MEFS and ESCs, E.G. and A.A.D. generated and performed experiments on PARPi-resistant tumours, J.J. and S.R. supervised the studies on PARPi-resistant tumours. N.W., A.D. and S.J. helped with experimentation, J.E.L. and K.G. generated Mll4- and Mll4-SET-deficient mice. L.S. and J.D. generated PTIP deletion constructs. B.S. provided reagents for experiments. D.C. provided advice on performing iPOND experiments and supervised iPOND mass spectrometry. J.C., N.P. and S.C. provided shCHD4 PEO1 cells and performed immunofluorescence experiments. P.K. analysed TCGA databases. V.F. and O.F.C. performed high-throughput image analysis of MRE11. S.S. supervised the ESC studies. A.R.C., E.C. and A.N. wrote the manuscript and all authors reviewed it.

Author Information Source tumour measurement data are provided in Supplementary Information. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to A.N. (andre_nussenzweig@nih.gov).
METHODS
Mice, MEFS, and B cell cultures. The 53Bp1−/− (ref. 37), Brca1fl/flΔ11(Δ11) (NCI mouse repository), Brca2fl/fl (NCI mouse repository), Rfflfl (ref. 27), Ptip67 (ref. 24) and Mll3fl/fl (ref. 38) mice have been described. To generate Mll3−SET/flox−/flox mice, exons 50–51 of the Mll3Kmt2d gene were flanked by loxP sites. Cre-mediated deletion of the floxed exons 50–51 causes frame shift and generates a stop codon in exon 52. The resulting protein lacks the carboxyl (C)-terminal 276 amino acids including the entire enzymatic SET domain. Resting splenic B cells were isolated from 12-week-old WT or mutagenized mice with anti-CD19 microbeads (anti-Ly48, Miltenyi Biotech) and were co-cultured with LPS (25 μg/ml; Sigma), IL-4 (5 ng/ml; Sigma) and RP105 (0.5 μg/ml; BD) as described34. Stimulated B cells were additionally fired with CRE to ensure a high level of gene deletion in these cells. All mice were randomly distributed in experimental groups after genotyping. WT MEFS were immortalized by SV40 retroviral infection, and SV40 immortalized Ptpi67 were infected with a CRE retrovirus to delete Ptpi and Mll3 respectively. Coding sequences for mouse Ptpi−GFP were cloned into the MIGR1 retroviral vector as previously described35. All cell lines used were tested for mycoplasma using a Mycoplasma Detection Kit (Invitrogen) and relevant cell lines were authenticated either by genotyping or western blot analysis. PARP inhibitor (KU55048) was obtained from AstraZeneca. Mirin was obtained from Sigma, PFM39 and WRN inhibitors were gifts from J. Tainer and R. Brosh respectively. DNA2 inhibitor has been described40. Cisplatin and HU were obtained from Sigma. For FISH analysis, metaphases were prepared and imaged as described41. Animal experiments were approved by the Animal Care and Use Committee of NCI-Bethesda and the Animal Ethical Committee of The Netherlands Cancer Institute.

Generation of CHD4-deficient PE01 lines using RNAi. BRCA2-mutated ovarian cancer cell lines PE01 were grown in DMEM with 10% FBS and 1% Glutamax. RNAi for CHD4 was performed as previously described28. ESCs were maintained in M15 media (Knockout DMEM with 15% fetal bovine serum). Rif1f/f mice were backcrossed to K14-cre;Brca2−/−K14-cre;Brca2−/−Mll4f/f (ref. 39) and Ptipf/f (ref. 37), Mll4−/−Ptipf/f mice were labelled with 10 μM EdU (Life Technologies) and treated with HU as indicated. Two hundred million cells were used for iPOND experiments with ESCs. Cells were cross-linked with 1% formaldehyde for 10 min at room temperature, quenched with 0.125 M glycine and washed with PBS. For the conjugation of EdU with biotin azide, cells were permeabilized with 0.25% Triton X-100/ PBS, and incubated in click reaction buffer (10 mM sodium-t.-ascorbate, 20 μM biotin azide (Life Technologies), and 2 mM CuSO4) for 2 h at room temperature. Cells were resuspended in lysis buffer (50 mM Tris–HCl, pH 8.0, and 1% SDS) supplemented with protease inhibitors (Roche), and chromatin was solubilized by sonication in a Bioruptor (Diagenode-Pico) at 4 °C for 24 min. After centrifugation, clarified supernatants were incubated for 1 h with streptavidin-MyOne C1 beads (Life Technologies). Beads were washed and captured proteins were eluted by boiling beads in 2× NuPAGE LDS Sample Buffer (Life Technologies) containing 200 mM DTT for 40 min at 95 °C. Proteins were resolved by electrophoresis using NuPAGE Novex 4–12% Bis–Tris gels and detected by western blotting with the indicated antibodies. For flow cytometric analysis, asynchronous B cells were pulsed with 10 μM EdU for 20 min at 37 °C and stained using the Click-IT EdU Alexa Fluor 488 Flow Cytometry Assay Kit according to the manufacturer’s specifications (ThermoFisher C-10425).

Generation of AZD2461-resistant KB2P tumours and in situ RAD51 assay. Brca2−/−p53−/− mammary tumours were generated in K14-cre;Brca2−/−p53−/− (KB2P) female mice and genotyped as described previously23. Orthotopic transplants into WT FVB/N/OLA (F1) mice, tumour monitoring, and sampling were conducted as described43. Starting from 2 weeks after transplantation, tumour size was monitored at least three times a week. All treatments were started when tumours reached a size of approximately 200 mm3. AZD2461 (100 mg/kg) was given orally for 28 consecutive days. If tumours did not shrink below 100% of the initial volume, treatment was continued for another 28 days. AZD2461 was diluted in 0.5% w/v hydroxypropyl methylcellulose in deionized water to a concentration of 10 mg/ml. For testing cross-resistance, mice were given a single treatment regimen of topotecan (2 mg/kg intraperitoneally, days 0–4 and 14–18) or cisplatin (Hay Pharma, 6 mg/kg intravenously, day 0). Statistical analysis was performed using GraphPad Prism (log-rank Mantel–Cox test). The in situ RAD51 irradiation induction formation assay has been described44.

Statistics. Statistics was performed by two-tailed t-test, Mann–Whitney test or by log-rank Mantel–Cox test unless otherwise specified. Statistical tests were justified appropriate for every figure. The data were normally distributed and the variance between groups being statistically compared was similar. No statistical methods or criteria were used to estimate sample size or to include/exclude samples. The investigators were not blinded to the group allocation during the experiments; however, the samples were coded before analysis unless otherwise specified.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Extended Data Figure 1 | Fork degradation in Brca-deficient B lymphocytes is mediated by MRE11 exonuclease activity. a, b, Ratio of IdU versus CldU upon HU treatment in WT, Brca1−/− (a) and WT, Brca2−/− (b) B lymphocytes with or without mirin pre-treatment. Numbers in red indicate the mean ± s.d. for each sample (**P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001, Mann–Whitney test). One hundred and twenty-five replication forks were analysed for each genotype. c, Ratio of IdU versus CldU upon HU treatment in Brca2−/− B lymphocytes with or without mirin, PFM39 (MRE11 exonuclease inhibitor), PC5 (DNA2 inhibitor) or WRNi pre-treatment. Numbers in red indicate the mean ± s.d. for each sample (**P ≤ 0.05, ****P ≤ 0.0001, Mann–Whitney test). One hundred and twenty-five replication forks were analysed for each genotype.
Extended Data Figure 2 | Replication fork progression rates and DSBs in B lymphocytes. a, Quantitative PCR analysis for Brca1, Brca2, Ptip and Rif1 gene deletions in WT, Brca1−/−, Brca1−/− Rif1−/−, Brca1−/− Ptip−/−, Brca2−/− Ptip−/− primary B lymphocytes after infection with CRE. b, PFGE analysis for detection of DSBs in WT, Brca2−/− and Brca2−/− Ptip−/− B lymphocytes treated with or without 4 mM HU for 3 h. Positive control for DSBs includes treatment of 15 Gy irradiation and HU + ATRi treatment for 3 h. Quantification of fold change in DSBs across genotypes relative to non-treated WT is plotted on the right. c–f, Replication fork progression rates, measured by tract lengths in micrometres, of CldU (red) and IdU (green) in WT, Brca1−/−, Brca1−/− 53Bp1−/−, Rif1−/−, Brca1−/− Rif1−/−, Ptip−/−, Brca1−/− Ptip−/−, Brca2−/− and Brca2−/− Ptip−/− primary B lymphocytes. Samples were not treated with HU. Numbers in red indicate the mean ± s.d. for each sample. One hundred and twenty-five replication forks were analysed for each genotype.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Extended Data Figure 3 | See next page for caption.
Extended Data Figure 3 | Loss of PTIP rescues fork progression and restart defects in Brca2-deficient B lymphocytes but does not affect RAD51 IRIF. a, Genomic instability measured in metaphase spreads from B lymphocytes derived from WT, Brca1−/−, Rif1−/−, Brca1−/−Rif1−/− mice treated for 6 h with 10 mM HU (∗P ≤ 0.05, unpaired t-test). Fifty metaphases were analysed per condition. Experiments were repeated three times. b, Genomic instability measured in metaphase spreads from B lymphocytes derived from WT, Brca2−/−, Ptip−/−, Brca2−/−Ptip−/− mice treated for 6 h with 10 mM HU (∗P ≤ 0.05, unpaired t-test). Fifty metaphases were analysed per condition. Experiments were repeated three times. c, Fork progression in B lymphocytes derived from WT, Brca2−/−, Ptip−/−, Brca2−/−Ptip−/− mice treated for 1 h with 0.2 mM HU. The y axis represents the tract lengths in micrometres. Numbers in red indicate the mean ± s.d. for each sample (****P ≤ 0.0001, Mann–Whitney test). One hundred and fifty replication forks were analysed for each genotype. d, Percentage of restarted replication forks in WT, Brca2−/−, Ptip−/−, Brca2−/−Ptip−/− B cells treated for 1 h with 1 mM HU followed by 90 min recovery. Two hundred replication forks were analysed for each genotype. e, Tract lengths of restarted replication forks in WT, Brca2−/−, Ptip−/−, Brca2−/−Ptip−/− B cells treated for 1 h with 1 mM HU followed by 90 min recovery. The y axis represents the tract lengths in micrometres. Numbers in red indicate the mean ± s.d. for each sample (NS, not significant, ****P ≤ 0.0001, Mann–Whitney test). One hundred and fifty replication forks were analysed for each genotype. f, Western blot analysis for RAD51 levels in WT, Ptip−/−, Brca2−/− and Brca2−/−Ptip−/− B cell extracts. Tubulin was used as loading control. g, Quantification of RAD51 foci formation in WT, Brca2−/− and Brca2−/−Ptip−/− B cells upon treatment with 5 and 10 Gy irradiation and recovery for 2, 4 and 6 h (n = 150 cells analysed).
Extended Data Figure 4 | See next page for caption.
Extended Data Figure 4 | Depletion of PTIP rescues the lethality of Brca2-deficient ESCs. a, Western blot analysis for PTIP levels in WT and two different clones of Brca2−/− ESCs electroporated with shPtip. b, Southern blot analysis for determination of Brca2 deletion in surviving clones electroporated with shPtip. Probes distinguishing the Brca2-flox allele (4.8 kb) (upper band) and Brca2 KO allele (2.2 kb) (lower band) were used. *Surviving ESC clones with Brca2 deletion and simultaneous downregulation of PTIP (12/96 Brca2-deleted colonies were found with shPtip1 and 3/60 colonies were found with shPtip2). Genotyping was confirmed by PCR (Fig. 2b). c, Top, representative FACS profiles of WT and Brca2−/−/shPtip ESCs electroporated with either pDR–GFP plasmid only (control) or pDRGFP and I-SceI expressing vector for 48 h. Gene conversion of the pDR–GFP construct by HR is determined by the percentage of GFP-positive cells (FL1, green-detection filter; FL2, red-detection filter). Bottom, quantification of the percentage of GFP-positive cells in WT and Brca2−/−/shPtip ESCs across three independent experiments. NS, not significant, *P ≤ 0.05, unpaired t-test. d, Sister chromatid exchange (SCE) analysis in WT and Brca2Y3308X hypomorphic ESCs. Twenty metaphases were analysed per condition; experiments were repeated three times. e, WT and Brca2Y3308X hypomorphic ESCs were preincubated with mirin, EdU-labelled for 15 min and treated with 4 mM HU for 2 h. Proteins associated with replication forks were isolated by iPOND and detected by western blotting with the indicated antibodies. f, SCEs in WT, Brca2−− and Brca2−−/− Ptip−− B cells either untreated or treated overnight with 1 μM PARPi or with 0.5 μM cisplatin (NS, not significant, *P ≤ 0.05, **P ≤ 0.001, unpaired t-test). Twenty metaphases were analysed per condition; experiments were repeated three times.
Extended Data Figure 5 | See next page for caption.
Extended Data Figure 5 | PTIP localizes to sites to DNA replication independently of DSBs. a, WT and 53Bp1−/− MEFs were retrovirally infected with a GFP-tagged PTIP construct. Cells were then irradiated with 10 Gy and allowed to recover. Co-localization of γ-H2AX (red) and PTIP (green) was assessed. Adjoining graph quantifies the percentage of cells with γ-H2AX foci co-localizing with PTIP upon irradiation (n = 150 cells analysed). Experiments were repeated three times. b, Western Blot analysis for endogenous and overexpressed PTIP levels in WT and 53Bp1−/− MEFs retrovirally infected with a GFP-tagged PTIP construct (GFP–PTIP). c, Quantification of the percentage of pan-nuclear γ-H2AX-positive cells with PTIP foci in WT and 53Bp1−/− MEFs upon treatment with HU (related to Fig. 3a) (n = 150 cells analysed). Experiments were repeated three times. d, Quantification of the percentage of cells with PTIP foci co-localizing with PCNA in WT and 53Bp1−/− MEFs in late S phase (related to Fig. 3b) (n = 150 cells analysed). Experiments were repeated three times. e, Representative immunofluorescence images of PCNA and 53BP1 co-staining in irradiated WT cells (10 Gy) or in late S-phase sites. White arrows indicate that the few 53BP1 foci observed in late S-phase cells do not co-localize with PCNA. (n = 50 cells analysed). Experiments were repeated three times. f, Representative immunofluorescence images of WT and Ptip−/− MEFs treated with 4 mM HU for 2 h and analysed for ssDNA (BrdU) and MRE11 co-localization. Bottom panels show the quantification of BrdU-positive cells (left) and the percentage of MRE11 co-localization in BrdU-positive cells (right) upon HU treatment in WT and Ptip−/− MEFs. (n = 150 cells analysed). Experiments were repeated three times. g, Quantification of the percentage of cells with MRE11 foci co-localizing with γ-H2AX upon irradiation treatment (10 Gy) in WT and Ptip−/− MEFs (related to Fig. 3e) (n = 150 cells analysed). Experiments were repeated three times. h, Cell cycle profiles in WT and Ptip−/− MEFs as measured by the incorporation of EdU (y axis) vs. DAPI (x axis). i, iPOND coupled to SILAC Mass-Spectrometry analysis for PTIP, H4 and RPA enrichment at stalled forks in 293T cells upon 3 mM HU treatment for 10 min and 4 h (ref. 22). The y axes represent the relative abundance of the indicated proteins on a log2 scale.
Extended Data Figure 6 | See next page for caption.
Extended Data Figure 6 | MLL3/4 promotes replication fork degradation in Brca2–deficient cells. a, Top, schematic of the retroviral PTIP mutant constructs used to identify the domain of PTIP involved in driving replication fork degradation. Different BRCT domains in PTIP are numbered and Q represents the glutamine rich region between the second and the third BRCT domains. Bottom, ratio of IdU versus CldU upon HU treatment of Brca2−/− Ptip−/− B lymphocytes retrovirally infected with either EV, FL, W165R, W663R and Del BRCT 5-6 PTIP-mutant constructs and sorted for GFP or mCherry expression. Numbers in red indicate the mean ± s.d. for each sample (**P ≤ 0.01, ****P ≤ 0.0001, Mann–Whitney test). One hundred and twenty-five replication forks were analysed for each condition. b, WT and Mll3/4−− MEFs were EdU-labelled for 15 min and treated with 4 mM HU for 4 h. Proteins associated with replication forks were isolated by iPOND and detected by western blotting with the indicated antibodies. c, Quantification of the percentage of cells with MRE11 foci co-localizing with PCNA in late S phase in WT and MLL3/4−/− MEFs (n = 150 cells analysed). Experiments were repeated three times. d–f, Ratio of IdU versus CldU upon HU treatment in WT, Brca1−/−, Brca2−/−, Mll4−/−, Mll4-SET−/−, Brca1−/− Mll4−/−, Brca2−/− Mll4−/− and Brca1−/− Mll4-SET−/− B cells. Numbers in red indicate the mean ± s.d. for each sample (NS, not significant, ****P < 0.0001, Mann–Whitney test). At least 125 replication forks were analysed for each genotype. g, Genomic instability measured in metaphase spreads from splenic B cells derived from WT, Brca2−/−, Mll4−/−, Brca2−/− Mll4−/− B cells treated overnight with 1 μM PARPi or with 0.5 μM cisplatin (**P ≤ 0.01, ****P ≤ 0.0001, unpaired t-test). Fifty metaphases were analysed per condition. Experiments were repeated three times.
Extended Data Figure 7 | Loss of RIF1 results in chromosomal instability. a, Quantification of RAD51 foci formation in WT, Brca1<sup>−/−</sup> and Rif1<sup>−/−</sup> B cells. Cells were treated with 10 Gy and harvested 4 h after irradiation (NS, not significant, *<i>P</i> ≤ 0.05). At least 100 cells were analysed per condition; experiments were repeated three times. b, c, Genomic instability measured in metaphase spreads from splenic B cells derived from WT, Brca1<sup>−/−</sup> and Rif1<sup>−/−</sup> mice treated overnight with 1 μM PARPi (b) or with 0.5 μM cisplatin (c) (NS, not significant, **<i>P</i> ≤ 0.01, ***<i>P</i> ≤ 0.001, ****<i>P</i> ≤ 0.0001, unpaired t-test). Fifty metaphases were analysed per condition; experiments were repeated three times.
Extended Data Figure 8 | See next page for caption.
Extended Data Figure 8  |  Multiple mutations can cause resistance to DNA-damaging agents in Brca-deficient cells.  

**a, b,** Difference in progression-free survival (PFS) of BRCA2- and BRCA1-mutated ovarian serous adenocarcinoma patients with standard platinum-based regimens. Data were obtained from the TCGA project. Patients were separated into PTIP low- or high-expression on the basis of the 33rd percentile of PTIP expression z-scores. The difference between the PFS of PTIP-low versus PTIP-high was assessed by univariate log-rank P value (P < 0.072 and P < 0.032 in a and b, respectively). Analysis included 38 tumours with BRCA1 mutations and 34 tumours with BRCA2 mutations out of 316 high-grade serous ovarian cancers that underwent whole-exome sequencing. PFS curves for PTIP-low and PTIP-high expressing tumours were generated by the Kaplan–Meier method. All reported P values are two-sided.  

**c,** Western blot analysis for CHD4 and PTIP levels in PEO1 cells infected with shNSC and shCHD4. Tubulin was used as loading control.  

**d,** Cell cycle profiles in PEO1 cells infected with shNSC and shCHD4 as measured by the incorporation of EdU (y axis) versus DAPI (x axis).  

**e,** Immunostaining for MRE11 and PCNA in PEO1 cells infected with shNSC and shCHD4 upon treatment with 4 mM HU. Bottom, quantification for MRE11 recruitment upon HU treatment. At least 100 cells were analysed per condition; experiments were repeated three times.  

**f,** Western blot analysis for CHD4 and MRE11 levels in PEO1 cells infected with shNSC and shCHD4. Actin was used as loading control.  

**g,** Percentage of EdU-positive cells was analysed 20 h after Brca2−/− B cells were treated with mirin alone, mirin + PARPi or mirin + cisplatin (NS, not significant). EdU was pulsed for 20 min before FACS analysis. Experiments were repeated three times.  

**h,** Genomic instability measured in metaphase spreads from B cells derived from Brca2−/− mice pretreated with 25 μM mirin for 2 h followed by overnight treatment with 1 μM PARPi or 0.5 μM cisplatin (NS, not significant, *P ≤ 0.05, **P ≤ 0.001, unpaired t-test). Fifty metaphases were analysed per condition. Experiments were repeated three times.  

**i,** Quantification of RAD51 foci formation in WT, Brca1−/−, Parp1−/− and Brca1−/− Parp1−/− B cells treated with 10 Gy irradiation and harvested 4 h after treatment. At least 100 cells were analysed per condition; experiments were repeated three times.
Extended Data Figure 9 | See next page for caption.
Extended Data Figure 9 | Brca2-deficient tumours acquire PARPi resistance without restoration of RAD51 foci formation. a, Schematic depicting the conditional BRCA2 allele of the KB2P (K14CRE;Brca2<sup>2<sup>/</sup>2</sup>;p53<sup>f/f</sup>) spontaneous tumour model. b, Outline of the PARPi intervention study. A spontaneous BRCA2-/p53-deficient tumour was generated and re-transplanted into syngeneic WT mice. When the tumours reached 200 mm<sup>3</sup>, they were treated either with vehicle or PARPi AZD2461. c, PARPi response curve of the KB2P tumour (relative tumour volume (rtv) versus days). The treatment for 28 consecutive days was started when the tumour reached 200 mm<sup>3</sup> (rtv = 100%). In response to the treatment, the tumour shrank but eventually grew back. When it reached 100% relative tumour volume, the treatment was repeated (as indicated with red arrows) for another 28 days. This regime was continued until the tumour became resistant to PARPi (black arrow). d, The stability of acquired resistance of the KB2P tumour was confirmed by re-transplanting matched naive and resistant tumours and treating animals either with vehicle or AZD2461 (only one 28-day cycle). Kaplan–Meier survival curve indicates that resistant tumours did not respond to the AZD2461 treatment, while naive tumours exhibited high sensitivity, indicative of a stable genetic mechanism of resistance. e, f, Irradiation-induced RAD51 foci were detected by immunofluorescence in the KB2P donor; RAD51 foci formation was undetectable in naive and resistant tumours, suggesting that HR restoration is not an underlying mechanism of PARPi resistance. Spontaneous tumours from K14 Cre; p53<sup>f/f</sup> mice treated with irradiation were used as positive control for RAD51 foci. Unirradiated K14 Cre; p53<sup>f/f</sup> cells were used as a negative control. g, Replication fork progression rates measured by tract lengths in micrometres of CldU (red) and IdU (green) in PARPi-naive or PARPi-resistant tumours. Numbers in red indicate the mean ± s.d. for each sample. One hundred and twenty-five replication forks were analysed for each condition. h, Western blot analysis for PTIP and MRE11 levels in PARPi-naive or PARPi-resistant tumours. Tubulin was used as loading control.
Extended Data Figure 10 | Brca2-deficient ESCs have higher levels of chromatin-bound MRE11. a, Representative image of a Brca2 hypomorph mouse ESC (denoted Brca2Y3308X) showing MRE11 foci (red) in S phase (identified by PCNA foci (green)). DNA was stained with DAPI (blue).

b, High-throughput microscopy analysis quantifying the overall levels of chromatin-bound MRE11 per individual nucleus in WT and Brca2Y3308X cells treated as indicated (a.u., arbitrary units).
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Xia Ding1, Arnab Ray Chaudhuri2, Elsa Callen2, Yan Pang1, Kajal Biswas1, Kimberly D. Klarmann1,3, Betty K. Martin1,3, Sandra Burkett1, Linda Cleveland1, Stacey Stauffer1, Teresa Sullivan1, Aashish Dewan1, Hanna Marks1, Anthony T. Tubbs2, Nancy Wong2, Eugen Buehler4, Keiko Akagi5, Scott E. Martin4,†, Jonathan R. Keller1,3, André Nussenzweig2 & Shyam K. Sharan1

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of synthetic lethality. Here we examine the effect of PARPi on HR-proficient cells. Olaparib pretreatment, PARP1 knockdown or Parp1 heterozygosity of Brca2cko/ko mouse embryonic stem cells (mESCs), carrying a null (ko) and a conditional (cko) allele of Brca2, results in viable Brca2ko/ko cells. PARP1 deficiency does not restore HR in Brca2ko/ko cells, but protects stalled replication forks from MRE11-mediated degradation through its impaired recruitment. The functional consequence of Parp1 heterozygosity on BRCA2 loss is demonstrated by a significant increase in tumorigenesis in Brca2cko/cko mice. Thus, while olaparib efficiently kills BRCA2-deficient cells, we demonstrate that it can also contribute to the synthetic viability if PARP is inhibited before BRCA2 loss.

1 Mouse Cancer Genetics Program, National Cancer Institute, NIH, Frederick, MD 21702, USA. 2 Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD 20893, USA. 3 Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. 4 Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA. 5 Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. † Present address: Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA 94080, USA. Correspondence and requests for materials should be addressed to A.N. (email: nussenza@exchange.nih.gov) or to S.K.S. (email: sharans@mail.nih.gov).
W
omen with a deleterious mutation in BRCA1 or BRCA2 have up to 70% risk of developing breast cancer by the age of 70 (ref. 1). It is well established that BRCA1 and BRCA2 function as tumour suppressors by maintaining genomic integrity. Both proteins are required for the repair of double-strand breaks (DSBs) by homologous recombination (HR) and also for the stability of stalled replication forks1–3. Their role in HR has been utilized to develop a therapeutic strategy that is based on the synthetic lethality of BRCA-deficient tumour by poly (ADP-ribose) polymerase (PARP) or ADP-riboseyltransferase diphtheria toxin-like, ARTD) inhibitors4–7.

PARPs consist of a family of enzymes that catalyse the formation of ADP-ribose polymers from NAD to glutamate, aspartate or lysine residues of target proteins. At least 18 members of the PARP family, have been identified based on the presence of a conserved catalytic domain. Poly ADP-ribosylation or parylation is a dynamic process as the ADP-ribose polymers can be rapidly degraded by poly (ADP-ribose) glycohydrolase and poly (ADP-ribose) hydrolase 3 (refs 8,9). PARP1, the founding member of the PARP family, has been shown to be stimulated in response to DNA damage. Parylation of target proteins by PARP1 results in decondensation of the chromatin near the site of DNA break, which is thought to facilitate the recruitment of DNA repair proteins10. Nevertheless, loss of PARP1 results in viable mice with no apparent defect except for the development of spontaneous tumours after a long latency and mild sensitivity to γ-radiation and alkylating agents11.

PARP inhibitors effectively kill BRCA-deficient tumour cells. Originally, it was proposed that PARP inhibitors caused an increase of single-strand breaks, which are converted to DSBs in the absence of HR, and are therefore toxic in the setting of BRCA deficiency4,5. Other plausible explanations for synthetic lethality include trapping of PARP1 at sites of DSBs or an increase in toxic non-homologous end joining in PARP1-deficient cells2,12,13. Regardless of the precise mechanism, PARP inhibitors such as olaparib continue to be the most promising and attractive treatment option for BRCA-deficient tumours because of their selectivity and apparent lack of toxicity in normal cells. Moreover, the repertoire of tumours that can be treated with PARP inhibitor (PARPi) is expanding to tumours with mutation in other genes associated with HR14.

Although only mild side effects have been reported from PARP treatment5,15,16, its off-target effects are poorly understood8. In this study, rather than treating HR-deficient cells with a PARPi, we treated HR-proficient Brca2cko/ko mouse embryonic stem cells (mESCs) to examine its effect on normal cells. We primarily used mESCs because they predominantly use HR to repair damaged DNA, and also loss of PARP1 does not affect their survival17,18. Surprisingly, we found that chemical inhibition, as well as PARP1 knockdown and heterozygosity of Parp1 rescued the lethality of Brca2-null mESC without restoring HR. PARP1 deficiency suppressed the recruitment of MRE11 nuclease to stalled replication fork, which contributed to fork protection in cells lacking BRCA2.

Results
Rescue of Brca2cko/ko mESC by PARP inhibition or deficiency. PARPi are selectively toxic to HR-deficient cells8,15. However, effects of PARPi are not limited to HR-deficient cells, as treatment of HR-proficient cells with different doses of olaparib resulted in suppression of CHK1 activation in response to replicative stress (Supplementary Fig. 1a), as reported previously19. To further examine the effect of olaparib on HR-proficient cells, we used PL2F7 mESCs that have one functionally null allele of Brca2 and the other is a conditional allele (Brca2cko/ko) (Supplementary Fig. 1b)20. We treated these cells with different doses of olaparib for 48–72 h and then deleted the k/o allele by transient expression of CRE. Cell cycle analysis showed these olaparib regimens did not overall significantly affect the cell cycle distribution (Supplementary Fig. 1c,d) or TRP53 and p19ARF stress responses (Supplementary Fig. 1h).

After expression of CRE, we selected the recombinant clones in HAT (hypoxanthine, aminopterin and thymidine) media because CRE-mediated deletion of k/o generates a functional HPRT minigene (Fig. 1a). Genotyping of the colonies did not reveal any Brca2cko/ko clones in untreated cells (n = 96), consistent with the fact that BRCA2 is essential for viability21. Remarkably, olaparib pretreatment resulted in a number of viable Brca2cko/ko cells at all doses tested (Fig. 1b) ranging from 4 to 8% of clones.

To test whether PARP1 deficiency in Brca2cko/ko cells would have similar functional consequences as observed with chemical inhibition of PARP, we generated two stably knocked-down clones using two different shRNAs against Parp1 (Fig. 1c). Parp1 stable knockdown clone had similar cell cycle distribution compared with nonsense control clone (Supplementary Fig. 1e–g). We again obtained several HAT-resistant mESC clones after k/o deletion. Genotyping of the clones revealed that up to 86% were Brca2cko/ko (Fig. 1d). These results demonstrate that PARP1 deficiency rescues the viability of Brca2cko/ko mESC.

To further strengthen these findings, we generated Parp1 knockout clones in PL2F7 cells by using CRISPR-Cas9 system to target exon 2 (Supplementary Fig. 2a,b). We used one Parp1 heterozygous (Parp1k/o+) clone and a compound heterozygous clone that was functionally null (Parp1k/o) for the mESC rescue experiment (Supplementary Fig. 2c–f). We obtained several Brca2cko/ko mESC clones from Parp1k/o+ PL2F7 cells (61%) confirming that the rescue of BRCA2 loss-induced mESC lethality by PARP1 deficiency (Supplementary Fig. 2g). However, no Brca2cko/ko mESC was obtained when we used Parp1k/o+ PL2F7 cells suggesting that these cells are sensitive to complete loss of both PARP1 and BRCA2, and residual PARP1 activity is required for survival of Brca2cko/ko mESC. Furthermore, the percentage of Brca2cko/ko mESC obtained on a Parp1 heterozygous background or by stable knockdown of PARP1 is high compared with 4–8% observed when cells were transiently treated with olaparib. This suggests that either prolonged PARP1 deficiency supports viability of Brca2cko/ko mESC better than transient inhibition or that PARPi, in addition to rescuing the BRCA2 loss, also results in toxicity to the cells.

We further validated the genetic interaction between BRCA2 and PARP1 by examining the consequence of PARP1 deficiency on the phenotype of Brca2cko/ko embryos. While no viable Brca2cko/ko pups were obtained from Parp1k/o+;Brca2cko/ko intercross, we did observe a significant rescue of the Brca2cko/ko embryos on Parp1k/+ genetic background (Supplementary Fig. 3,c,d). At E8.5, Parp1+/+;Brca2cko/ko embryos were severely retarded and disorganized, whereas Parp1k/o+;Brca2cko/ko embryos had undergone gastrulation and exhibited well-developed extra embryonic structures (Supplementary Fig. 3c). At E10.5, we did not obtain any Parp1k/o+;Brca2cko/ko embryos (Supplementary Fig. 3e) indicating that these embryos die between E9.5 and E10.5. Consistent with the mESC results, we did not obtain any Parp1k/o+;Brca2cko/ko embryos at E8.5 by either Parp1k/o+;Brca2cko/ko intercross or Parp1k/o+;Brca2cko/ko crossed with Parp1k/o+;Brca2cko/ko (Supplementary Fig. 3a,b), indicating that complete loss of PARP1 and BRCA2 is detrimental to mESC, as well as mouse embryos. These results suggest that PARP1 is essential for the viability of Brca2 null cells, likely due to its wide-ranging biological functions6.
HR is not restored by PARP1 deficiency in Brca2\(^{ko/ko}\) mESC. BRCA2 is essential for the recruitment of RAD51 at DSB to mediate HR\(^{1,21}\). We therefore examined whether RAD51 recruitment in response to DSB induction was restored in the Brca2\(^{ko/ko}\) mESC rescued by PARP1 knockdown or by olaparib treatment. We did not observe any RAD51 foci in these cells in response to irradiation, although RAD51 was expressed at levels similar to the control cells (Fig. 2a and Supplementary Fig. 4a,b). Next, we used gene targeting to measure DSB-induced HR efficiency in the rescued cells\(^{20}\). We compared PL2F7 controls with or without PARP1 knockdown with two Brca2\(^{ko/ko}\) mESCs rescued by PARP1 knockdown. While control and PARP1 knockdown cells exhibited a targeting efficiency of 16.7–25\%, Brca2\(^{ko/ko}\) rescued cells did not exhibit any targeted clones (Fig. 2b). Moreover, metaphase spreads revealed an increase in chromosomal aberrations in Brca2\(^{ko/ko}\) mESC rescued by PARP1 knockdown compared with the parental PL2F7 cells (Supplementary Fig. 4c.d). Together with the defect in RAD51 foci formation, these results demonstrate that DSB-induced HR is not restored in rescued Brca2\(^{ko/ko}\) mESC.

**Rescue of Brca2\(^{ko/ko}\) haematopoietic cells by PARP1 treatment.**

Given the pro-survival effects of PARP1 deficiency or PARP inhibition on the viability of Brca2\(^{ko/ko}\) mESC in vitro, we tested whether olaparib treatment in vivo can support survival of Brca2-deficient haematopoietic progenitor cells. Wild-type (WT) and Brca2\(^{ko/cko}\) mice were injected with either dimethylsulfoxide (DMSO) or olaparib for 10 days and then collected the bone marrow (Fig. 3a). We then transduced the bone marrow cells with CRE-GFP lentivirus to delete the conditional allele. Green fluorescent protein (GFP)-positive cells were sorted and cultured in vitro for colony formation. DMSO- and olaparib-pretreated WT cells formed an average of 428 and 485 colonies per plate, respectively. In contrast, the DMSO-pretreated Brca2\(^{ko/ko}\) cells formed very few and small colonies (average of 104 per plate). While olaparib-pretreated Brca2\(^{ko/ko}\) cells also formed small colonies, their number was significantly higher (average of 104 per plate). Brca2cko/cko cells remained unchanged (Fig. 3b,c). This suggests that the surviving olaparib-pretreated Brca2\(^{ko/ko}\) cells were indeed HR-defective and BRCA2-deficient, which was confirmed by genotyping (Fig. 3d).

**PARP1 deficiency protects degradation of replication forks.**

BRCA2 has been reported to protect replication forks from degradation, independent of its role in DSB repair by HR\(^2\). PARP1 has been shown to play important roles in the control of...
several aspects of replication fork dynamics, including fork restart, degradation and reversal\textsuperscript{22–24}. Since cell viability is not associated with restoration of the HR defect, we therefore asked whether PARP1 deficiency conferred replication fork stability to Brca2\textsuperscript{ko/ko} mESC rescued by PARP1 knockdown. Integrity of the replication forks was examined using the DNA fibre assay, which allows single-molecule resolution of replication fork tracts\textsuperscript{2}. Ongoing replication forks were labelled with chlorodeoxyuridine (CldU; red) and then with iododeoxyuridine (IdU; green) for 15 min each followed by fork stalling agent, hydroxyurea (HU) treatment for 3 h. We measured the track length of CldU- and IdU-labelled DNA fibres and calculated the IdU to CldU ratio. The ratio is close to 1 when the forks are protected, but <1 when the forks are degraded. While WT cells exhibited an average ratio of IdU to CldU tracts lengths close to 1, IdU tracts in mESC expressing a truncated allele of BRCA2 (Brca2\textsuperscript{ko/ko}) were considerably shorter (average IdU to CldU ratio = 0.807, $P<0.0001$, Mann–Whitney test), indicating the degradation of nascent strands on replicative stress (Fig. 4a,b). Strikingly, in both Brca2\textsuperscript{ko/ko} clones rescued by PARP1 knockdown, IdU to CldU ratios were comparable to those observed in PL2F7 cells (average IdU to CldU ratio = 1.09 and 1.12, respectively) (Fig. 4a,b). These results indicate that deficiency of PARP1 deficiency confers protection to the replication forks in the absence of functional BRCA2.

To determine whether the observed replication fork protection due to PARP1 deficiency is observed in other cell types, we also analysed replication fork integrity in mouse B lymphocytes. For reasons not well understood, unlike mESCs, B cells are able to tolerate loss of ‘essential’ HR genes (for example, BRCA1, BRCA2 and CtIP) with minimal impact on their growth ex vivo\textsuperscript{25,26}. Nevertheless, these cells remain highly sensitive to agents that challenge replication forks\textsuperscript{25,26}. We generated B lymphocytes from WT, Parp1\textsuperscript{ko/ko}, Brca2\textsuperscript{ko/ko} and Parp1\textsuperscript{ko/ko};Brca2\textsuperscript{ko/ko} mice. The cko allele was deleted by transducing the cells with CRE-expressing retrovirus after stimulating B cells with lipopolysaccharide + interleukin-4 and RP105. Deletion of the cko allele was confirmed by quantitative PCR (Fig. 4c). On HU treatment, the average IdU to CldU ratios were determined to be 0.957, 0.976, 0.624 and 0.979 for WT, Parp1\textsuperscript{ko/ko} and Brca2\textsuperscript{ko/ko}Parp1\textsuperscript{ko/ko};Brca2\textsuperscript{ko/ko} cells, respectively (Fig. 4d,e). Thus, consistent with our observation in mESC, loss of PARP1 resulted in protection of the nascent strand in Parp1\textsuperscript{ko/ko};Brca2\textsuperscript{ko/ko} B cells ($P=0.1147$ versus WT, Mann–Whitney test).

To test whether deficiency of PARP1 can rescue fork degradation induced by BRCA2 loss in human cells as well, we used immortalized human mammary epithelial cells MCF10A. Two independent clones with stable PARP1 knockdown were generated by transducing cells with shRNA-expressing lentivirus (Fig. 4f). We then knocked down BRCA2 by siRNA (Fig. 4g) and examined fork stability by DNA fibre assay. Average IdU to CldU ratios were 1.03, 0.64 and 0.66 in stable control clone with nonsense, BRCA2-1 and BRCA2-2 siRNA, respectively. However, the average ratios were 1.00, 0.89 and 0.95 in stable PARP1 knockdown clone with nonsense, BRCA2-1 and BRCA2-2 siRNA, respectively. This was consistent with our observation in mESC, loss of PARP1 resulted in protection of the nascent strand in Parp1\textsuperscript{ko/ko};Brca2\textsuperscript{ko/ko} cells ($P=0.0001$, Mann–Whitney test) (Fig. 4h,i). Thus, consistent with our observation in mESC, loss of PARP1 resulted in protection of the nascent strand in Parp1\textsuperscript{ko/ko};Brca2\textsuperscript{ko/ko} B cells ($P=0.1147$ versus WT, Mann–Whitney test).

![Figure 2](https://example.com/figure2.png)

**Figure 2 | HR is not restored by PARP1 deficiency in Brca2\textsuperscript{ko/ko} mESC.** (a) Immunofluorescence images showing RAD51 foci formation 5 h after 10 Gy irradiation (IR). RAD51 foci were assessed at a single time point with a single dose of irradiation (IR). Olap pretreat;Brca2\textsuperscript{ko/ko} indicates Brca2\textsuperscript{ko/ko} mESC rescued by olaparib pretreatment. Scale bars, 10 $\mu$m. (b) Histogram showing gene-targeting efficiency. shPARP1-1/2; Brca2\textsuperscript{ko/ko} indicates Brca2\textsuperscript{ko/ko} mESC rescued by PARP1 knockdown. Actual numbers of targeted clones and total numbers of clones are indicated above each column. Inset shows Southern blot of the gene targeting.
BRCA2 loss-induced fork degradation in both mouse and human cells.

Impaired MRE11 recruitment contributes to fork protection.

We next examined the molecular mechanism of the fork protection that may contribute to rescue of Brca2\(^{cko/ko}\) mESC. MRE11 nucleolytic activity is responsible for BRCA2 loss-induced fork degradation\(^{2,24}\). MRE11 is reported to interact with PARP1 (refs 22,27). Interestingly, MRE11 has a PAR-binding RG or RGG-rich motif suggesting that it may be PARylated by PARP1 (refs 9,27). We therefore investigated whether the effect of PARP1 deficiency was mediated via MRE11. Our data confirmed previous reports that MRE11 physically interacts with PARP1 independent of replication stress and presence of DNA; however, this interaction was disrupted when PARP was inhibited by olaparib (Fig. 5a and Supplementary Fig. 5d). We further identified the N-terminal region of PARP1 containing two Zn finger domains but not the catalytic domain to interact with MRE11. Our findings suggest that PARP1 and MRE11 interaction was dependent on PARP activity (Supplementary Fig. 5a–c). Since the interaction is mediated by PARP1 N-terminal instead of its catalytic domain, we also speculate that auto-PARylation of PARP1 may be important for PARP1 and MRE11 interaction. The fact that interaction between PARP1 N-terminal domain and MRE11 can also be disrupted by olaparib (Supplementary Fig. 5c) suggests that the N-terminal domain might be auto-PARylated.

Consistent with previous studies\(^7\), we observed rescue of the fork degradation in Y3308X BRCA2-expressing mESC by MRE11 inhibitor, mirin (Supplementary Fig. 6a), indicating MRE11 indeed mediates the fork degradation in BRCA2-deficient mESC.

To determine whether PARP inhibition or PARP1 deficiency affected recruitment of MRE11 to stalled replication forks, we examined the presence of MRE11 at the fork in mESC treated with HU (4 mM, 4 h) or HU with olaparib (1 µM, 2 h pretreatment followed by HU combination for another 4 h) by iPOND (isolation of proteins on nascent DNA)\(^{28}\). HU treatment induced marked increase in MRE11 recruitment to stalled replication forks. However, olaparib reduced the association of MRE11 to stalled replication forks (Fig. 5b). To examine the effects of PARP1 deficiency, we performed iPOND by using mESC with PARP1 knockdown (Supplementary Fig. 6e), as well as Parp1\(^{cko/ko}\)-immortalized mouse embryonic fibroblasts (MEFs) (Fig. 5c and Supplementary Fig. 6b). Consistently, we observed a marked reduction of MRE11 recruitment in these
Figure 4 | PARP1 deficiency protects BRCA2 loss-induced replication fork degradation. (a) Scattered plot showing DNA fibre analysis of indicated cell lines. ****P<0.0001, ns, not significant (Mann–Whitney test). (b) Representative images of DNA fibres as quantified in a. (c) qPCR showing the deletion of genomic Brca2 DNA in B cells with the indicated genotypes. All the cells were infected by retrovirus-Cre. Primers are listed in Supplementary Note 1. ****P<0.0001, ns, not significant (t-test). (d) Scattered plot showing DNA fibre analysis in B cells. (e) Representative images of DNA fibres as quantified in d. (f) Western blot showing PARP1 level in MCF10A stable knockdown cells. (g) Western blot showing BRCA2 knockdown level by siRNA in PARP1 stable knockdown MCF10A clones. (h) Scattered plot showing DNA fibre analysis in MCF10A cells, ****P<0.0001 (Mann–Whitney test). (i) Representative images of DNA fibres quantified in h.
PARP1-deficient cells. Furthermore, compared with PL2F7 cells, we detected a clear reduction in MRE11 recruitment at the fork in two independent Brca2<sup>ko/ko</sup> mESC clones rescued by PARP1 knockdown (Fig. 5d and Supplementary Fig. 6c). On the basis of the above results, we conclude that impaired recruitment of MRE11 to stalled replication forks by PARP inhibition or PARP1 deficiency contributes to fork protection in Brca2<sup>ko/ko</sup> mESC.

If fork protection indeed contributes to the rescue of Brca2<sup>ko/ko</sup> mESC survival, it is difficult to reconcile the survival of Brca2<sup>ko/ko</sup> mESC rescued by olaparib, because the olaparib-mediated inhibitory effect is transient. We therefore tested whether transient PARPi treatment was indeed sufficient to rescue Brca2<sup>ko/ko</sup> mESC lethality. We pretreated PL2F7 cells with 10 μM olaparib for only 3 h and then performed the rescue experiment as described in Fig. 1a. Surprisingly, even such transient exposure to olaparib resulted in a number of viable Brca2<sup>ko/ko</sup> mESC clones (24%) (Fig. 5e). This is in line with the iPOND analysis, which revealed that olaparib disrupts the MRE11 recruitment to the stalled fork (Fig. 5b). Unlike the Brca2<sup>ko/ko</sup> mESC rescued by PARP1 knockdown, Brca2<sup>ko/ko</sup> mESC rescued by olaparib resulted in fork degradation (Supplementary Fig. 6d,g). These cells also had significantly

Figure 5 | Impaired MRE11 recruitment contributes to fork protection and cell survival after BRCA2 loss. (a) Western blot of immunoprecipitation in HEK293T cells showing interaction of MRE11 and PARP1. (b) Western blot of iPOND samples in PL2F7 cells showing MRE11 and Histone H3 levels at the replication fork. HU, 4 mM, 4 h (same as below). Olaparib (Olap), 1 μM, 2 h pretreatment, with HU for 4 h. (c) Western blot of iPOND samples in MEF cells showing MRE11 and Histone H3 levels at the replication fork. (d) Western blot of iPOND samples from indicated cell lines showing MRE11 and Histone H3 levels at the replication fork. Numbers indicate quantification of relative band intensity of MRE11 normalized to Histone H3. These band intensities were compared with the intensity of MRE11 in PL2F7 cells, which was considered to be 1. (e) Representative Southern blot showing rescue of Brca2<sup>ko/ko</sup> mESC by transient olaparib or mirin pretreatment. (f) Western blot showing MRE11 level in stable knockdown mESC clones. Numbers indicate quantification of relative band intensity of MRE11 normalized to corresponding ACTIN band intensity. These band intensities were compared with the intensity of MRE11 in Nonsense, which was considered to be 1. (g) Representative Southern blot showing rescue of Brca2<sup>ko/ko</sup> mESC in two MRE11 stable knockdown clones. Asterisks indicate the rescued clones.
more breaks and gaps than the cells rescued by PARP1 knockdown (Supplementary Fig. 4c,d). These results suggest transient fork protection during the deletion of Brca2 may contribute to rescue the survival of Brca2ko/ko mESC, however, the subsequent survival of Brca2ko/ko cells is not dependent on fork protection.

**Rescue of Brca2ko/ko mESC by MRE11 inhibition or deficiency.**

To directly test whether MRE11 inhibition can rescue the lethality of Brca2ko/ko mESC, we pretreated PL2F7 cells with 100 μM mirin (the same dosage that can rescue fork degradation as shown in Supplementary Fig. 6a) for 3 h and then performed the rescue experiment described in Fig. 1a. We obtained a number of Brca2ko/ko mESC (22%, Fig. 5e). Like other BRCA2-null rescued mESC described above, these cells lacked irradiation-induced RAD51 foci (Supplementary Fig. 6f,h), indicating that HR was not restored. To rule out any off-target effects of mirin, we generated MRE11 stable knockdown clones by shRNA in PL2F7 cells (Fig. 5f). Consistent with the rescue by mirin, MRE11 stable knockdown resulted in the survival of Brca2ko/ko mESC as evident in two independent MRE11 knockdown clones (Fig. 5g). Although we cannot rule out the possibility that other genetic and epigenetic alterations or effects on cell cycle regulation induced by PARP or MRE11 inhibition or knockdown may contribute to viability, our findings suggest that fork protection may play an important role in rescue of cellular viability. We also conclude that while transient fork protection by either PARP1 or MRE11 inhibition contributes to the initial survival of Brca2ko/ko mESC, it is not essential to maintain the growth of these cells (Fig. 6).

**Brca2ko/cKO mice are tumour prone in a Parp1ko/+ background.** It is known that mESC lethality due to BRCA1 loss can be rescued by 53BP1 loss, which restores resection and HR, and suppresses tumorigenesis in mice. In contrast, PARP1 deficiency does not restore HR but results in fork protection. Although the fork protection promotes genomic stability relative to cells that lack fork protection (Supplementary Fig. 4c,d), the level of genomic instability is higher than the cells expressing WT BRCA2. We predict that viable cells exhibiting genomic instability are likely to contribute to tumorigenesis. To directly test whether PARP inhibition or PARP1 deficiency can facilitate tumorigenesis in BRCA2-deficient mice, we generated K14-Cre;Brca2ko/cKO mice on Parp1+/- and Parp1ko/+ genetic backgrounds. We observed a marked increase in the incidence of epithelial tumours in K14-Cre;Brca2ko/cKO mice in a Parp1ko+/- genetic background (23 out of 56 mice, 41.1%) compared with that in Parp1+/- genetic background (2 out of 18 mice, 11.1%; P = 0.0226, Fisher’s exact test; Fig. 7a, Supplementary Fig. 7 and Supplementary Table 1), suggesting PARP1 deficiency indeed facilitates BRCA2 loss-induced tumorigenesis.

**Discussion**

PARylation by PARP1 affects the cellular localization and site-specific recruitment, such as recruitment to DNA damage sites, of a number of proteins involved in a wide-range of biological processes. Here we have investigated the functional consequence of PARP inhibition on HR-proficient cells that express functional BRCA2. PARPi is toxic to BRCA2-deficient cells, however, we show that PARP inhibition can paradoxically promote their survival. We show that knockdown or heterozygous loss of Parp1, as well as olaparib treatment before BRCA2 loss rescues the lethality of Brca2ko/ko mESC. We speculate that the order of two genetic events, PARP inhibition or PARP1 deficiency and BRCA2 loss, dictates the outcome of either synthetic lethality or synthetic viability (Fig. 6). Inactivation of PARP1 before loss of BRCA2 is likely to promote survival by preventing MRE11-mediated toxicity linked to DNA replication and subsequent cell death. In contrast, in BRCA2-null cells, MRE11 may persist at the replication forks and degrade it, causing persistent DNA damage. This genomic instability would be exacerbated and result in cell death by the subsequent PARPi due to the additional block in single-strand break repair or perhaps due to the PARP1 trapping.

The role of MRE11 in cell viability by PARP inhibition or PARP1 deficiency is demonstrated by the rescue of Brca2ko/ko mESC by knockdown of MRE11, as well as by treatment of cells with mirin before BRCA2 loss. Although our findings suggest that the MRE11-mediated fork protection by PARP inhibition or PARP1 deficiency may contribute to the rescue of Brca2ko/ko mESC, it is not essential for maintaining cell survival even in the absence of HR. For example, a short treatment of olaparib or mirin rescues Brca2ko/ko mESC. What contributes to the viability in this case is puzzling because the rescued cells are unable to protect the fork in response to replication stress. We hypothesize that when PARP or MRE11 are inhibited and the conditional allele of Brca2 is deleted, cells are able to overcome the
BRC2-null crisis (that is, BRC2 loss-induced excessive fork degradation, fork collapse resulting in un-repairable DSBs causing cell death) because the replication forks are transiently protected due to defect in MRE11 recruitment. We propose that this transient fork protection may be sufficient for the initial survival. Once the cells survive the BRC2-null crisis, their survival is no longer dependent on PARP inhibition or fork protection (Fig. 6). These results therefore suggest that the rescued cells may acquire epigenetic changes or secondary mutations perhaps through mutagenic non-homologous end joining or sister chromatid exchanges, which are indeed enhanced by PARP inhibition or PARP1 deficiency (Supplementary Fig. 4c–e).13,31,32

Interestingly, in an independent study, MRE11 recruitment to nascent DNA strands was shown to be dependent on PTIP and the associated histone methyltransferases MLL3 and MLL4 (ref. 33). Similar to PARP1 deficiency, PTIP loss inhibits degradation of stalled forks and rescues the viability of Brc2<sup>ko/ko</sup> mESC. An important functional consequence of fork protection associated with PTIP loss is resistance to PARPi and cisplatin in Brc2-deficient tumour cells that is independent of the presence of secondary reversion mutations. Similar association between fork protection and PARPi or cisplatin resistance was also observed with CHD4 los<sub>33,34</sub>. Together, this study and our present study highlight the importance of fork protection in rescuing BRC2 loss-associated phenotypes without restoration of HR.

Our ability to rescue the lethality of Brc2<sup>ko/ko</sup> cells may have important implications. We predict that in addition to killing the tumour cells, PARPi may facilitate the survival of normal BRC2 heterozygous cells that undergo loss of heterozygosity. These cells that will otherwise undergo apoptosis may be able to survive and have the potential to become neoplastic (Fig. 7b). Taken together, our findings provide evidence that PARPi, although lethal to HR-deficient cancers, is not innocuous in HR-proficient normal cells.

**Methods**

mESC culture. All mESCs were cultured on mitotically inactive SNL feeder cells in M15 media, which is Knockout DMEM media (Life Technologies) supplemented with 15% fetal bovine serum (FBS; Life Technologies), 0.00072% beta-mercaptoethanol, 100 U ml<sup>−1</sup> penicillin, 100 μg ml<sup>−1</sup> streptomycin and 0.292 mg ml<sup>−1</sup> l-glutamine at 37 °C, 5% CO<sub>2</sub>. All culture media were supplemented with 2% N2 supplements. After electroporation, 2x10<sup>4</sup> mESCs suspended in 0.9 ml PBS using Gene Pulser (Bio-Rad) at 230 V, 500 F were electroporated into 1 ml of mESC culture media and 2 ml of fresh M15 media. 20 μg ml<sup>−1</sup> DNA was used. After electroporation, 2x10<sup>4</sup> mESCs were plated into 10 cm plate and G418 selection (0.18 mg ml<sup>−1</sup>) was started 24 h after electroporation. G418 was withdrawn after 5 days of selection for colonies to become visible. Individual colonies were picked into 96-well plate and PARP1 knockdown level of each clone was determined by western blot.

**Generation of PARPi stable knockdown mESC clones**. Two different shRNAs against mouse *Parp1* mRNA and one control shRNA (nonsense) were cloned into pSUPERIOR.retro.neo vector (Oligoengine) into BglII and HindIII restriction sites. After electroporation, 2x10<sup>4</sup> mESCs suspended in 0.9 ml PBS using Gene Pulser (Bio-Rad) at 230 V, 500 F were electroporated into 1 ml of mESC culture media and 2 ml of fresh M15 media. 20 μg ml<sup>−1</sup> DNA was used. After electroporation, 2x10<sup>4</sup> mESCs were plated into 10 cm plate, and G418 selection (0.18 mg ml<sup>−1</sup>) was started 24 h after electroporation. G418 was withdrawn after 5 days of selection for colonies to become visible. Individual colonies were picked into 96-well plate and PARP1 knockdown level of each clone was determined by western blot.

**Generation of *Parp1* knockout clones in mESC by CRISPR-Cas9.** Small guide RNA (sgRNA) was designed within exon 2 of mouse *Parp1* gene by using CRISPR design tool at http://crispr.mit.edu. The oligonucleotide sequences are listed in Supplementary Note 1. Oligonucleotides were cloned into Cas9 nickase (Cas9n) expression vector pX335-U6-Chimeric_BB-CBh-hSpCas9n (D10A) (Addgene, plasmid #42335). Oligonucleotides were cloned into the vector to generate sgRNAs. SURVEYOR nuclease assay was performed by transfecting sgRNA into NHEJ DT3 cells and PCR amplifying the edited genomic region. Nuclease S was used to digest the re-annealed PCR products<sup>35</sup>. Primers for SURVEYOR nuclease assay are listed in Supplementary Note 1.
For sgRNA transfection in mESC, 3 x 10^5 mESCs were plated in 6-well plates 24 h before transfection. sgRNAs (1 µg of each) were co-transfected with pcDNA3.1 (1 µg) plasmid (Life Technologies) by using 12 µl FuGENE 6transfection reagent (Promega). Cells were trypsinized and 1 x 10^6 cells were re-plated into 10 cm plate 24 h after transfection. G418 selection (0.18 mg ml^-1) was started 24 h after re-plating. G418 selection was performed for 5 days followed by growth in M15 media for 2 days and then normal M15 media until colonies became visible. Individual colonies were picked into 96-well plate and PCR was performed to amplify the targeted region. PCR primers are listed in Supplementary Note 1. PCR products of clones having band sizes different from WT band were purified and sequenced. PARP1 protein expression of each clone was determined by western blot.

Deletion of Brca2 cko allele and selection of Brca2^cko/cko mESC. A unit of 20 µg of PGK-Cre plasmid DNA were electroporated into 1 x 10^6 mESCs suspended in 0.9 ml PBS by Gene Pulser (Bio-Rad) at 230 V, 500 µF. HAT selection was started 36 h after electroporation and lasted for 5 days, followed by selection in HT media for 2 days and then normal M15 media until colonies became visible. Colonies were picked into 96-well plate. For extracting genomic DNA, colonies were lysed in 50 µl mESC buffer (10 mM Tris-HCl (pH 7.4), 10 mM EDTA, 10 mM NaCl, 5 mg ml^-1 sodium lauroyl sarcosinate, 1 mg ml^-1 proteinase K) at 55°C overnight, and DNA was precipitated by 100 µl 75 mM NaCl in absolute ethanol. Genomic DNA was rinsed by 70% ethanol and digested by EcoRV at 37°C overnight for Southern blot.

Southern blot. EcoRV-digested DNA was electrophoresed on 1% agarose gel in 1 x TBE (0.1 M Tris, 0.1 M boric acid and 2 mM EDTA, pH 8.0) and transferred to nylon membrane for probe detection. Probes used for Southern blot were Brca2 (^4.8 kb) and Brca2 knockout allele (ko-Brca2, 2.2 kb) and was labelled with 32P using [α-32P]-CTP by Prime-It II Random Prime Labeling Kit (Agilent Technologies) and hybridized with Hybond-N + nylon membrane (GE Healthcare) at 65°C overnight. Membrane was washed twice with saline sodium citrate phosphate (SSC) buffer containing 0.1% SDS in and exposed in phosphor image screen overnight and subsequently developed in Typhoon image scanner.

Mice and tumour pathology. Brca2^2m Animals carry a null allele of Brca2 and CD19-Cre expressing Cre transgene under the control of CD18 promoter were used23,24. K14-Cre and Brca2^cko/cko mice were obtained from NCI-Frederick mouse repository (strain number:01XF1 and 01XB9, respectively)25. Purified Brca2^cko/cko mice were obtained from Jackson Laboratory (stock number: 002779)13. All genotyping primers are listed in Supplementary Note 1. These mice were crossed to generate mice of desired genotypes. Mice of each genotype were randomly selected for experiments. Mice necropsy was performed by NCI-Frederick Pathology and Histotology Laboratory. Tumours were evaluated by blindly a board-certified veterinary pathologist, who was blinded to the group allocation.

All animal studies were performed as per the guidelines outlined in the Guide for the Care and Use of Laboratory Animals and protocols approved by the NCI-Frederick Animal Care and Use Committee.

Embryo dissection and laser capture microdissection. Timed pregnancy in mice was set up and embryos were collected at E8.5 or E10.5. Embryos were dissected according to established protocol26,27. Dissected embryos were lysed in 50 µl mESC lysis buffer (2% SDS, 10% glycerol, 0.1 M dithiothreitol and 0.2 M Tris-HCl pH 7.4) on glass slides and incubated in click reaction buffer (10 mM sodium-L-ascorbate, 20 mM biotin azide (Life Technologies) and 2 mM CuSO4) for 2 h at room temperature. Cells were resuspended in lysis buffer (50 mM Tris-HCl (pH 8.0) and 1% SDS) supplemented with protease inhibitors (Roche), and chromatin was solubilized by sonication in a Bioruptor (Diagenode-Pico) for 4°C for 24 min. After centrifugation, supernatants were incubated for 1 h Streptavidin-MycOne C1 beads (Life Technologies). Beads were washed and captured proteins were eluted by boiling beads in 2 x NuPAGE LDS Sample Buffer (Life Technologies) containing 200 mM dithiothreitol for 40 min at 95°C. Proteins were resolved by electrophoresis using NuPAGE Novex 4-12% Bis-Tris gels and detected by western blot with the indicated antibodies. HR assay. HR assay was performed by gene-targeting assay28. Briefly, mESCs were electroporated by the targeting vector and were selected in hygromycin. Colonies were picked and targeted clones were identified by Southern hybridization.

DNA fibre assay. DNA fibre assay was performed by aligning DNA fibre with EdU (Life Technologies) and treated with 4 µM HU for 4 h as indicated29. Cells were crosslinked with 1% formaldehyde for 10 min at room temperature, quenched with 0.1 M glycine and washed with PBS. For the conjugation of EdU with biotin, cells were permeabilized with 0.25% Triton X-100 in PBS buffer, and incubated in click reaction buffer (10 mM sodium-ascorbate, 20 mM biotin azide (Life Technologies) and 2 mM CuSO4) for 2 h at room temperature. Cells were resuspended in lysis buffer (50 mM Tris-HCl (pH 7.4), 0.5% SDS) on glass slides and incubated at room temperature for 8 min before DNA fibre was spread. Fibres were fixed in methanol and acetic acid (3:1) at 4°C overnight, rehydrated by PBS and delysed for 20 min. Rinsing away of PBS by PBS was blocked in PBS with 5% bovine serum albumin (BSA) for 1 h and incubated with anti-BrDu antibody (Mouse, #347580, Becton Dickinson, 1:100 dilution) and anti-BrDu antibody (Rabbit, ab36262, Abcam, 1:100 dilution) at 4°C overnight. Slides were rinsed with PBS with 0.1% Tween-20 (PBST) and incubated with AlexaFluo488-conjugated anti-mouse IgG secondary antibody and AlexaFluo594-conjugated anti-rat IgG secondary antibody for 1 h at room temperature. Slides were rinsed with PBST and mounted by mounting media (Prolong Gold, Invitrogen). Images were taken in Zeiss Axio Imager Z1 microscope and fibre length was measured by ImageJ software (NIH).

Protein expression and interaction studies. The following antibodies were used: anti-PARP1 (Rabbit, #9542, Cell Signaling Technology); anti-PARP2 (Rabbit, ab93416, Abcam); anti-GAPDH (Rabbit, #2118, Cell Signaling Technology); anti-ACTIN (Goat, sc-1616, Santa Cruz); anti-RAD51 (Rabbit, PC130, Calbiochem); anti-hH2AX (Mouse, 05–636, Millipore); anti-pS317 CHK1 (Rabbit, #13202, Cell Signaling Technology); anti-hCHK1 (Mouse, sc-8408, Santa Cruz); anti-MRE11 (Goat, sc-5859, Santa Cruz); anti-MRE11 (Rabbit, Calben and Nakamura, unpublished); anti-MYC (Mouse, D60I, Zymed); anti-MYC (Rabbit, 2272, Cell Signaling Technology); anti-pS55 (Mouse, 2524, Cell Signaling Technology); anti-pS15 pS15 (Rabbit, 9284, Cell Signaling Technology); anti-Histone H3 (Rabbit, 9715, Cell Signaling Technology); anti-PCNA (Rabbit, 13110, Cell Signaling Technology); anti-p19ARF (Rabbit, ab80, Abcam); and anti-MAF (Mouse, 328349, Cell Signaling Technology). For characterization of cell lines, cells were lysed in SDS lysis buffer (2% SDS, 10% glycerol, 0.1 M dithiothreitol and 0.2 M Tris-HCl (pH6.8)) and subjected to SDS–PAGE gel electrophoresis, and subsequently...
transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.

For immunoprecipitation, cells were lysed in IP buffer (30 mM Tris-HCl (pH 8.0), 75 mM NaCl, 10% glycerol and 0.5% Triton X-100) containing protease inhibitors (Complete Mini protease inhibitor cocktail tablets, Roche) at 4°C for 15 min and subjected to centrifugation at 15,000g for 15 min at 4°C. Supernatant was transferred and added 30 µl beads (Protein G sepharose 4 Fast Flow, GE Healthcare) together with 2 µg indicated antibodies and incubated on rocker at 4°C for 4 h. Beads were washed three times by IP buffer at 800g for 1 min each time. Proteins were dissociated from the beads by SDS lysis buffer and boiled at 95°C for 10 min. For the immunoprecipitation with DNase treatment, DNase I (200 ng/ml) was added and incubated for 30 min at 37°C. The reaction was stopped by adding 200 µl of 2× Laemmli buffer. Samples were run on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.

For immunoprecipitation, cells were lysed in IP buffer (30 mM Tris-HCl (pH 8.0), 75 mM NaCl, 10% glycerol and 0.5% Triton X-100) containing protease inhibitors (Complete Mini protease inhibitor cocktail tablets, Roche) at 4°C for 15 min and subjected to centrifugation at 15,000g for 15 min at 4°C. Supernatant was transferred and added 30 µl beads (Protein G sepharose 4 Fast Flow, GE Healthcare) together with 2 µg indicated antibodies and incubated on rocker at 4°C for 4 h. Beads were washed three times by IP buffer at 800g for 1 min each time. Proteins were dissociated from the beads by SDS lysis buffer and boiled at 95°C for 10 min. For the immunoprecipitation with DNase treatment, DNase I (200 ng/ml) was added and incubated for 30 min at 37°C. The reaction was stopped by adding 200 µl of 2× Laemmli buffer. Samples were run on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.

For immunoprecipitation, cells were lysed in IP buffer (30 mM Tris-HCl (pH 8.0), 75 mM NaCl, 10% glycerol and 0.5% Triton X-100) containing protease inhibitors (Complete Mini protease inhibitor cocktail tablets, Roche) at 4°C for 15 min and subjected to centrifugation at 15,000g for 15 min at 4°C. Supernatant was transferred and added 30 µl beads (Protein G sepharose 4 Fast Flow, GE Healthcare) together with 2 µg indicated antibodies and incubated on rocker at 4°C for 4 h. Beads were washed three times by IP buffer at 800g for 1 min each time. Proteins were dissociated from the beads by SDS lysis buffer and boiled at 95°C for 10 min. For the immunoprecipitation with DNase treatment, DNase I (200 ng/ml) was added and incubated for 30 min at 37°C. The reaction was stopped by adding 200 µl of 2× Laemmli buffer. Samples were run on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.

For immunoprecipitation, cells were lysed in IP buffer (30 mM Tris-HCl (pH 8.0), 75 mM NaCl, 10% glycerol and 0.5% Triton X-100) containing protease inhibitors (Complete Mini protease inhibitor cocktail tablets, Roche) at 4°C for 15 min and subjected to centrifugation at 15,000g for 15 min at 4°C. Supernatant was transferred and added 30 µl beads (Protein G sepharose 4 Fast Flow, GE Healthcare) together with 2 µg indicated antibodies and incubated on rocker at 4°C for 4 h. Beads were washed three times by IP buffer at 800g for 1 min each time. Proteins were dissociated from the beads by SDS lysis buffer and boiled at 95°C for 10 min. For the immunoprecipitation with DNase treatment, DNase I (200 ng/ml) was added and incubated for 30 min at 37°C. The reaction was stopped by adding 200 µl of 2× Laemmli buffer. Samples were run on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.

For immunoprecipitation, cells were lysed in IP buffer (30 mM Tris-HCl (pH 8.0), 75 mM NaCl, 10% glycerol and 0.5% Triton X-100) containing protease inhibitors (Complete Mini protease inhibitor cocktail tablets, Roche) at 4°C for 15 min and subjected to centrifugation at 15,000g for 15 min at 4°C. Supernatant was transferred and added 30 µl beads (Protein G sepharose 4 Fast Flow, GE Healthcare) together with 2 µg indicated antibodies and incubated on rocker at 4°C for 4 h. Beads were washed three times by IP buffer at 800g for 1 min each time. Proteins were dissociated from the beads by SDS lysis buffer and boiled at 95°C for 10 min. For the immunoprecipitation with DNase treatment, DNase I (200 ng/ml) was added and incubated for 30 min at 37°C. The reaction was stopped by adding 200 µl of 2× Laemmli buffer. Samples were run on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with the indicated primary antibodies at 4°C overnight, washed by PBST and probed with corresponding horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h and subjected to ECL (Amersham). For immunofluorescence, cells were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100 and blocked with 3% BSA. Cells were incubated with the indicated primary antibodies at 4°C overnight. After washing four times with PBST, cells were incubated with AlexaFluor488-conjugated anti-rabbit IgG antibody and AlexaFluor568-conjugated anti-mouse IgG antibody (Life Technologies) at room temperature for 2 h. Nucleus was counterstained by 4,6-diamidino-2-phenylindole. Images were taken on Zeiss LSM 510 confocal microscope.


Acknowledgements

We thank members of our laboratory for helpful discussions and suggestions. We also thank the staff of NCI-Frederick Pathology and Histotechnology Laboratory for help with tumour analysis. We thank Dr Terry Yamaguchi (NCI-Frederick, NIH) for help with phenotypic analysis of mouse embryos. We thank Dr John Petrini and Shawn Fox (MSKCC) for MRE11 expression construct. This research was sponsored by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, US National Institutes of Health. X.D. received Department of Defense, Breast Cancer Research Program, Postdoctoral Fellowship (W81XWH-13-1-0362).

Author contributions

X.D. designed and performed experiments, analysed data and wrote the manuscript; A.R.C. and E.C. designed and performed experiments and analysed data; K.B. performed experiments and analysed data; K.D.K. and J.R.K. helped with HSC experiments and data analysis; Y.P., L.C., S.S., T.S., A.D., H.M., A.T.M. and N.W. helped with experiments; B.K.M. assisted with animal studies; S.B. performed cytogenetic analysis; E.B., K.A. and S.E.M. helped with data analysis; A.N. contributed to experimental design, data analysis and manuscript writing; S.K.S. conceived and supervised the study, analysed data and wrote the manuscript.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Ding, X. et al. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. *Nat. Commun.* **7**:12425 doi: 10.1038/ncomms12425 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016